WO2021048850A1 - Chimeric antigen receptor comprising cd40 cytoplasmic domain and uses thereof - Google Patents
Chimeric antigen receptor comprising cd40 cytoplasmic domain and uses thereof Download PDFInfo
- Publication number
- WO2021048850A1 WO2021048850A1 PCT/IL2020/050991 IL2020050991W WO2021048850A1 WO 2021048850 A1 WO2021048850 A1 WO 2021048850A1 IL 2020050991 W IL2020050991 W IL 2020050991W WO 2021048850 A1 WO2021048850 A1 WO 2021048850A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- domain
- nucleic acid
- acid molecule
- cell
- amino acid
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 33
- 230000001086 cytosolic effect Effects 0.000 title description 3
- 101150013553 CD40 gene Proteins 0.000 claims abstract description 48
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims abstract description 48
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 37
- 230000019491 signal transduction Effects 0.000 claims abstract description 37
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 35
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 35
- 230000003213 activating effect Effects 0.000 claims abstract description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 76
- 230000003834 intracellular effect Effects 0.000 claims description 74
- 239000013598 vector Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 101100226902 Mus musculus Fcrlb gene Proteins 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 13
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 claims description 10
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 claims description 10
- 230000000735 allogeneic effect Effects 0.000 claims description 8
- 230000000447 dimerizing effect Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 210000003289 regulatory T cell Anatomy 0.000 claims description 6
- 108010060889 Toll-like receptor 1 Proteins 0.000 claims description 5
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims description 4
- 108010087819 Fc receptors Proteins 0.000 claims description 4
- 102000009109 Fc receptors Human genes 0.000 claims description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 4
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 claims description 4
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 claims description 4
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims description 4
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 4
- 102000008229 Toll-like receptor 1 Human genes 0.000 claims description 4
- 102000008228 Toll-like receptor 2 Human genes 0.000 claims description 4
- 108010060888 Toll-like receptor 2 Proteins 0.000 claims description 4
- 102000008234 Toll-like receptor 5 Human genes 0.000 claims description 4
- 108010060812 Toll-like receptor 5 Proteins 0.000 claims description 4
- 108091008108 affimer Proteins 0.000 claims description 4
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 108091023037 Aptamer Proteins 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 10
- 210000004027 cell Anatomy 0.000 description 55
- 150000001413 amino acids Chemical group 0.000 description 35
- 108020004999 messenger RNA Proteins 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 16
- 239000000427 antigen Substances 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 230000011664 signaling Effects 0.000 description 15
- 230000004913 activation Effects 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 201000001441 melanoma Diseases 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 238000004520 electroporation Methods 0.000 description 9
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 8
- 108010038807 Oligopeptides Proteins 0.000 description 7
- 102000015636 Oligopeptides Human genes 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 5
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- UYYRDZGZGNYVBA-UHFFFAOYSA-N 2-[2-chloro-4-[3-(3-chloro-4-hydroxyphenyl)-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(Cl)C(O)=CC=2)C=C1Cl UYYRDZGZGNYVBA-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000022534 cell killing Effects 0.000 description 4
- 230000000139 costimulatory effect Effects 0.000 description 4
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 3
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 102000004393 TNF receptor-associated factor 2 Human genes 0.000 description 3
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000004068 intracellular signaling Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 241000710929 Alphavirus Species 0.000 description 2
- 108700031361 Brachyury Proteins 0.000 description 2
- 238000011357 CAR T-cell therapy Methods 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 241001227713 Chiron Species 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 240000007019 Oxalis corniculata Species 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 2
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000003468 luciferase reporter gene assay Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- -1 CD3- z Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001663880 Gammaretrovirus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 1
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 231100000416 LDH assay Toxicity 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 1
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102000004398 TNF receptor-associated factor 1 Human genes 0.000 description 1
- 108090000920 TNF receptor-associated factor 1 Proteins 0.000 description 1
- 102000004399 TNF receptor-associated factor 3 Human genes 0.000 description 1
- 108090000922 TNF receptor-associated factor 3 Proteins 0.000 description 1
- 102000003718 TNF receptor-associated factor 5 Human genes 0.000 description 1
- 108090000001 TNF receptor-associated factor 5 Proteins 0.000 description 1
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Definitions
- the present invention relates in general to activating chimeric antigen receptors (aCARs) and their use in immunotherapy of cancer.
- CAR-T cells face major obstacles posed by both extrinsic and intrinsic factors.
- the transferred T cells are confronted by the resilient tumor microenvironment, which often recruits immune suppressor cells, including regulatory T cells (Tregs), myeloid derived suppressor cells and tumor-associated macrophages and exploits diverse evasion mechanisms to prevent T cell access and avoid an immunological attack [6].
- Tregs regulatory T cells
- myeloid derived suppressor cells and tumor-associated macrophages
- TNFR tumor necrosis factor receptor
- APCs antigen-presenting cells
- 4-1BB CD137
- TNFR tumor necrosis factor receptor
- the TNFR family also includes 0X40 and CD27, whose signaling elements have similarly been assessed in advanced CAR designs.
- the cytosolic portions of these TNFRs bear structural similarities and they all signal through adaptor TNFR-associated factor (TRAF) proteins via the NFKB, p38 MAPK or JNK/SAPK pathways [14].
- CD28 was shown to support the rapid acquisition of effector functions and tumor eradication capacity but only limited persistence, both in apparent contrast to 4- IBB (e.g., [10,16,17]).
- 4- IBB e.g., [10,16,17]
- CD28 mostly induces CAR-T cell differentiation into the effector-memory type
- 4- IBB preferentially drives central memory formation [18].
- engrafting these two costimulatory domains in tandem to create 3 rd generation CARs does not necessarily result in improved therapeutic activity in-vivo (see [8] for a recent review).
- the present invention provides a nucleic acid molecule comprising a nucleotide sequence encoding an activating chimeric antigen receptor (aCAR) comprising: (i) an extracellular binding domain capable of binding to an antigen; (ii) a transmembrane domain; (iii) an intracellular domain; and (iv) a flexible hinge or stalk domain linking the extracellular binding domain and the transmembrane domain, said flexible hinge or stalk domain comprising a cysteine residue capable of forming a cysteine bridge thereby forming an aCAR homodimer, wherein said intracellular domain is selected from:
- an intracellular domain comprising at least one signal transduction element derived from CD40 and a second amino acid sequence comprising at least one signal transduction element derived from an FcR gamma (g) chain, CD3 zeta (z) chain, or CD3 eta (h) chain, and lacking a MyD88 polypeptide, 2A self-cleaving peptide or a dimerizing domain;
- an intracellular domain comprising a first amino acid sequence comprising at least one signal transduction element derived from CD40, a second amino acid sequence comprising at least one signal transduction element derived from an FcR gamma (g) chain, CD3 zeta (z) chain, or CD3 eta (h) chain and a third amino acid sequence comprising at least one signal transduction element derived from CD28; and
- an intracellular domain comprising a first amino acid sequence comprising at least one signal transduction element derived from CD40 and lacking a MyD88 polypeptide or a truncated MyD88 polypeptide lacking the Toll/IL-1 receptor domain (TIR) domain and may alternatively or further lack a myristoylation-targeting sequence or a dimerizing domain, such as an FKBP12v36 domain.
- TIR Toll/IL-1 receptor domain
- the present invention provides a composition comprising the nucleic acid molecule of any one of any one of the above embodiments.
- the present invention provides a vector comprising the nucleic acid molecule of any one of the above embodiments.
- the present invention provides a mammalian T cell comprising the nucleic acid molecule of any one of the above embodiments, or the DNA vector of any one of the above embodiments.
- the present invention provides a method of preparing allogeneic or autologous aCAR T cells, the method comprising contacting T cells with the nucleic acid molecule of any one of any one of the above embodiments; or a DNA vector as defined above, thereby preparing allogeneic or autologous aCAR T cells.
- the present invention provides a method of treating or preventing a disease, disorder or condition in a subject, comprising administering to said subject the mammalian T cell of any one of the above embodiments, wherein said T cell is a CD8 + effector T cell and said disease, disorder or condition is selected from a solid tumor, hematologic malignancy, melanoma, infection with a virus; or said T cell is a CD4 + regulatory T cell (Treg) and said disease, disorder or condition is manifested in excessive activity of the immune system, such as an autoimmune disease, allergy, asthma, and organ and bone marrow transplantation.
- a disease, disorder or condition in a subject, comprising administering to said subject the mammalian T cell of any one of the above embodiments, wherein said T cell is a CD8 + effector T cell and said disease, disorder or condition is selected from a solid tumor, hematologic malignancy, melanoma, infection with a virus; or said T cell is a CD4 + regulatory T
- Fig. 1 shows a schematic representation of the eight CARs, where “Li” refers to the first flexible peptide linker of the single chain variable fragment, and “T” refers to the Myc tag.
- Fig. 2 shows CAR surface expression.
- K562 cells were transfected by electroporation with 10 qg of each of the indicated mRNAs. Twenty-four hours later cells were subjected to flow cytometry analysis for expression of the Myc tag. Black histograms, irrelevant mRNA; grey histograms, CARs. See Fig. 1 for key to CAR names.
- Figs. 3A-B shows CAR functionality.
- A Antigen- specific activity of the new CARs (see Fig. 1 for key to CAR names).
- B3Z T cells possessing the reporter NFAT-LacZ gene were electroporated with each of the indicated mRNAs. Seven hours post-electroporation cells were incubated at 1:1 ratio with 579 melanoma cells (checkered), 579-A2 melanoma cells (black) or no cells (white), and 24 hours later cell lysates were subjected to the colorimetric CPRG assay.
- B Activation of the NF-KB signaling pathway.
- HEK293T cells were transfected with the NF-KB- luciferase reporter plasmid and 24 hours later with mRNA encoding each of the indicated constructs. Histograms show relative luminescence units (RLU) in cell lysates. 201, activation by anti-CD3 mAh; Irr., irrelevant mRNA; P.C., positive control, constitutively active CD40 (caCD40, (7)). Results are representative of three independent experiments.
- RLU relative luminescence units
- Figs. 4A-F show antigen- specific activation of human CD8 T cells.
- CD8 T cells of Donor I (A-C) and Donor II (D-F) that were electroporated with CAR mRNA and subjected to expression and function analyses (see Fig. 1 for key to CAR names).
- ELISA for the secretion of pro- inflammatory cytokines IFN-g (A, D), TNF-a (B, E), GM-CSF (C, F).
- Figs. 5A-B show LDH assay for target cell (579 melanoma cells (white) or 579-A2 melanoma cells (black)) killing by cells obtained from Donor I (A) and Donor II (B). Results shown in ‘A’ represent three, and in ‘B’ two, independent experiments, all performed separately for CD8 T cells of each of the two donors.
- CD40 is a member of the TNFR family and is mainly expressed by professional APCs.
- a number of studies suggest that CD40 is functionally expressed also by T cells.
- the direct T cell stimulatory capacity of CD40 was manifested in a wide range of effects including differentiation, memory formation, improvement of functional avidity, upregulation of anti-apoptotic signals and decreasing pro-apoptotic ones, rescue from exhaustion and acquisition of resistance to Treg- mediated suppression [20-22].
- other studies failed to confirm these observations and the immunological role played by T cell-expressed CD40 under physiological conditions is still elusive.
- the potent costimulatory capacity of the CD40 signaling domain has successfully been recruited to native unmodified T cells [23-25].
- others have found that CD40 signaling domains are inactive in the context of aCARs unless they are conjugated with self-assembly and myD88 domains [26-28].
- the inventors of the present invention have constructed a series of new anti-HLA-A2 CARs harboring either the intracellular signaling domain of CD40 or of 4-1BB, with or without the intracellular signaling domain of CD28, and examined these CARs in mRNA-electroporated human CD8 T cells. Schematic presentation of the series of constructs examined is depicted in Fig. 1 and detailed in Table 1. It was unexpectedly found that the mere incorporation of the CD40 signaling domain in the intracellular portion of the different CARs led to spontaneous activation of the NF-KB signaling pathway, which was consistently higher than that induced by the corresponding CARs harboring the 4-1BB signaling domain (Fig. 2B).
- CD40 signaling domain was fully potent in these T cells, as manifested by the introduction of either caCD40 or of native CD40, followed by CD40L stimulation [24].
- the present invention a nucleic acid molecule comprising a nucleotide sequence encoding an activating chimeric antigen receptor (aCAR) comprising: (i) an extracellular binding domain capable of binding to an antigen; (ii) a transmembrane domain; (iii) an intracellular domain; and (iv) a flexible hinge or stalk domain linking the extracellular binding domain and the transmembrane domain, said flexible hinge or stalk domain comprising a cysteine residue capable of forming a cysteine bridge thereby forming an aCAR homodimer, wherein said intracellular domain is selected from:
- an intracellular domain comprising at least one signal transduction element derived from CD40 and a second amino acid sequence comprising at least one signal transduction element derived from an FcR gamma (g) chain, CD3 zeta (z) chain, or CD3 eta (h) chain, and lacking a MyD88 polypeptide, 2A self-cleaving peptide or a dimerizing domain;
- an intracellular domain comprising a first amino acid sequence comprising at least one signal transduction element derived from CD40, a second amino acid sequence comprising at least one signal transduction element derived from an FcR gamma (g) chain, CD3 zeta (z) chain, or CD3 eta (h) chain and a third amino acid sequence comprising at least one signal transduction element derived from CD28; and
- an intracellular domain comprising a first amino acid sequence comprising at least one signal transduction element derived from CD40 and lacking a MyD88 polypeptide or a truncated MyD88 polypeptide lacking the Toll/IL-1 receptor domain (TIR) domain and may alternatively or further lack a myristoylation-targeting sequence or a dimerizing domain, such as an FKBP12v36 domain [29].
- the signal transduction element derived from CD40 may be a tumor necrosis factor receptor (TNFR)-associated factor (TRAF) -binding domain, e.g. TRAF2, TRAF3, TRAF5 and TRAF6 binding domain.
- TRAF2, 3 and 5 usually have overlapping binding motifs, whereas TRAF6 has a distinct interacting motif on these receptors, and TRAF1 binds to the CD40 signal transduction element via TRAF2 [30].
- the signal transduction element derived from the FcR gamma (g) chain, CD3 zeta (z) chain, or CD3 eta (h) chain is an immunoreceptor tyrosine-based activation motif (IT AM).
- IT AM immunoreceptor tyrosine-based activation motif
- This motif contains a tyrosine separated from a leucine or isoleucine by any two other amino acids, giving the signature YxxL/I. Two of these signatures are typically separated by between 6 and 8 amino acids in the cytoplasmic tail of the molecule (YxxL/Ix(6-8)YxxL/I).
- a T cell or cell population comprising a T cell expressing the aCAR of the present invention has an increased cytotoxic activity against a cell having the target antigen on the surface, as compared to a T cell or cell population comprising a T cell expressing an aCAR whose intracellular domain consists of an intracellular domain of CD28 and O ⁇ 3z, 4-1BB and O ⁇ 3z, or CD28 and 4- IBB.
- the extracellular binding domain comprises (i) an antibody, derivative or fragment thereof, such as a humanized antibody; a human antibody; a functional fragment of an antibody; a single-domain antibody, such as a Nanobody; a recombinant antibody; and a single chain variable fragment (ScFv); (ii) an antibody mimetic, such as an affibody molecule; an affilin; an affimer; an affitin; an alphabody; an anticalin; an avimer; a DARPin; a fynomer; a Kunitz domain peptide; and a monobody; or (iii) an ap tamer.
- an antibody, derivative or fragment thereof such as a humanized antibody; a human antibody; a functional fragment of an antibody; a single-domain antibody, such as a Nanobody; a recombinant antibody; and a single chain variable fragment (ScFv);
- an antibody mimetic such as an affibody molecule
- the extracellular binding domain comprises an ScFv.
- the ScFv comprises a Variable Light chain (VL) and a Variable Heavy chain (VH) linked by a first flexible peptide linker, e.g. of SEQ ID NO: 12.
- the transmembrane domain of the aCAR is selected from the transmembrane domain of CD28, CD40, CD3- z, TLR1, TLR2, TLR4, TLR5, TLR9, and Fc receptor.
- the transmembrane domain is the CD28 transmembrane domain, e.g. of SEQ ID NO: 16.
- the transmembrane domain is the CD40 transmembrane domain, e.g. of SEQ ID NO: 22.
- the first amino acid sequence is the complete intracellular domain of CD40, e.g. of SEQ ID NO: 17.
- the at least one signal transduction element of the second amino acid sequence is derived from an FcRy chain.
- the second amino acid sequence is the complete intracellular domain of an FcRy chain, e.g. of SEQ ID NO: 18.
- the third amino acid sequence is the complete intracellular domain of CD28, e.g. of SEQ ID NO: 20.
- the flexible hinge or stalk comprises a polypeptide selected from a hinge region of CD8a or O ⁇ 8b.
- the sequence and structure of these hinge domains are well- characterized (e.g. Wong et al. [31]).
- the flexible hinge or stalk may further by selected from a hinge region of a heavy chain of IgG, and a hinge region of a heavy chain of IgD.
- the flexible hinge domain is the hinge domain of CD8a, e.g. a complete flexible hinge domain, optionally altered by the addition of two Ser residues at its C- terminus (to form an Xhol restriction site), such as in the sequence of SEQ ID NO: 15.
- the nucleic acid molecule of any one of the above embodiments comprises a nucleotide sequence encoding an aCAR comprising an extracellular binding domain comprising (i) an antibody, derivative or fragment thereof, such as a humanized antibody; a human antibody; a functional fragment of an antibody; a single-domain antibody, such as a Nanobody; a recombinant antibody; and a single chain variable fragment (ScFv); (ii) an antibody mimetic, such as an affibody molecule; an affilin; an affimer; an affitin; an alphabody; an anticalin; an avimer; a DARPin; a fynomer; a Kunitz domain peptide; and a monobody; or (iii) an aptamer; said transmembrane domain is selected from the transmembrane domain of CD28, CD40, CDS-z, TLR1, TLR2, TLR4, TLR5, TLR9, and
- the flexible hinge comprises a polypeptide selected from a hinge region of CD8a, O ⁇ 8b, a hinge region of a heavy chain of IgG, and a hinge region of a heavy chain of IgD.
- the aCAR of the previous embodiment comprises an extracellular binding domain comprising an ScFv; the transmembrane domain is the transmembrane domain of CD28 e.g. of SEQ ID NO: 16; the second amino acid sequence is the complete intracellular domain of an FcRy chain, e.g. of SEQ ID NO: 18; and the flexible hinge domain is the flexible hinge domain of CD8a.
- the intracellular domain of any one of the above aCARs comprises or essentially consists of a tandem arrangement of the complete intracellular domains of CD40- FcRy.
- the intracellular domain of any one of the above aCARs comprises or essentially consists of a tandem arrangement of the complete intracellular domains of CD28- CD40-FcRy, wherein the intracellular domain of CD28 is optionally linked to the intracellular domain of CD40 via a short oligopeptide linker.
- tandem arrangement is selected from a polypeptide comprising the complete intracellular domains of [N-terminus-CD28]-[optional short oligopeptide linker] -[CD40- FcRy-C-terminus]; and [N-terminus- CD40]-[FcRy-C-terminus].
- the order of appearance of the different domains from N- to C-terminus can be different, e.g. [N-terminus-CD40]-[optional short oligopeptide linker]-[CD28-FcRy-C-terminus] .
- the intracellular domain of any one of the above aCARs comprises or essentially consists of the complete intracellular domains of 4- IBB, CD40, and FcRy.
- the aCAR may comprise an ScFv; the transmembrane domain of CD28; the complete intracellular domain of CD40, the complete intracellular domain of 4- IBB, the complete intracellular domain of an FcRy chain; and the flexible hinge domain of CD8a.
- Flexible peptide linkers are well-known in the art. Empirical linkers designed by researchers are generally classified into three categories according to their structures: flexible linkers, rigid linkers, and in vivo cleavable linkers as defined e.g. in [32-34], each one of which is incorporated by reference as if fully disclosed herein.
- the structure of the flexible short oligopeptide linker is selected from any one of the linkers disclosed in [32-34].
- the linkers are generally composed of small, non-polar (e.g. Gly) or polar (e.g. Ser or Thr) amino acids, such an underlying sequence of alternating Gly and Ser residues.
- Solubility of the linker and associated signal transduction elements may be enhanced by including charged residues; e.g. two positively charged residues (Lys) and one negatively charged residue (Glu).
- the linker may vary from 2 to 31 amino acids, optimized for each condition so that the linker does not impose any constraints on the conformation or interactions of the linked partners in lengths.
- the flexible short oligopeptide linker has the amino acid sequence Gly-Gly-Gly
- the intracellular domain comprises or essentially consists of a tandem arrangement of the complete intracellular domains of [CD28]-[ short oligopeptide linker]- [CD40]-[FcRy] (from N- to C-terminus). (28-40-g)
- the aCAR comprises a tandem arrangement of (from N- to C- terminus) [ScFv]-[hinge region of CD8a-CD28 transmembrane domain] -[intracellular domain essentially consisting of a tandem arrangement of the complete intracellular domains of CD40- FcRyj. (40-g)
- the aCAR comprises a tandem arrangement of (from N- to C- terminus) [ScFv]-[hinge region of CD8a-CD28 transmembrane domain] -[intracellular domain essentially consisting of a tandem arrangement of the complete intracellular domains of CD28- CD40-FcRy], wherein the intracellular domain of CD28 is optionally linked to the intracellular domain of CD40 via a linker.
- the DNA or amino-acid sequence of each one of the different domains of the aCAR is the human sequence.
- the aCAR excluding the extracellular binding domain, comprises the combined amino acid sequences of SEQ ID NOs: 15+16+20+Gly-Gly-Gly+17+18; or 15+16+17+18.
- Non-limiting examples of complete sequences of DNA encoding aCARs of the present invention are set forth in SEQ ID NOs: 25, 27, 29, 31, 33, 35, 37, and 39; and non-limiting examples of complete amino acid sequences of aCARs of the present invention are set forth in 26, 28, 30, 32, 34, 36, 38, and 40. It should be made clear that these are examples disclosed for the sole purpose of teaching one specific way of making the present invention, which can be easily adapted by a person skilled in the art to fulfill different experimental demands, e.g. by the introduction or abolishment of enzyme restriction sites or short flexible oligopeptide linkers as required, or by synonymous changes in the DNA sequence to improve expression.
- the different domains, and full sequence, of the aCARs defined above may have amino acid sequences that have at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85 %, at least 90 %, or at least 95, 96, 97, 98, or 99% identity to the sequences defined in SEQ ID NO: 15, 16, 17, 18, 20, 26, 28, 30, 32, 34, 36, 38, and 40 and other combined sequences recited above, respectively, as long as the aCAR is active, i.e. is capable of activating a T cell in an antigen-dependent manner.
- nucleotide sequences encoding the various domains of the aCAR defined above comprise ah redundant nucleotide sequences encoding the amino acid sequences of these domains as well as similar sequences encoding for active aCARs.
- nucleotide sequences encoding for amino acid sequences of SEQ ID NO: 15, 16, 17, 18, 20, 26, 28, 30, 32, 34, 36, 38, and 40 are as set forth in SEQ ID NO: 6, 7, 8, 9, 20, 25, 27, 29, 31, 33, 35, 37, and 39, respectively; or any other redundant sequence encoding for identical amino acid sequences.
- nucleotide sequences may have at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85 %, at least 90 %, or at least 95, 96, 97, 98, or 99% identity to the sequences defined in SEQ ID NO: 6, 7, 8, 9, 19, 25, 27, 29, 31, 33, 35, 37, and 39, and the nucleotide sequences encoding for other combined amino acid sequences recited above, respectively, as long as the encoded aCAR is active, i.e. is capable of activating a T cell in an antigen-dependent manner.
- the intracellular domain of (c) or (d) of any one of the above embodiments lacks MyD88 polypeptide or a truncated MyD88 polypeptide lacking the Toh/IL-1 receptor domain (TIR) domain and may alternatively or further lack a myristoylation-targeting sequence or a dimerizing domain, such as an FKBP12v36 domain.
- TIR Toh/IL-1 receptor domain
- the intracellular domain of (a) (b), (c) or (d) of any one of the above embodiments lacks a self-cleaving peptide, such as 2A self-cleaving peptide including any one of P2A, E2A, F2A and T2A.
- a self-cleaving peptide such as 2A self-cleaving peptide including any one of P2A, E2A, F2A and T2A.
- the present invention provides a composition comprising the nucleic acid molecule of any one of any one of the above embodiments.
- Matuskova and Durinikova teach that there are two systems for the delivery of transgenes into a cell - viral and non-viral.
- the non- viral approaches are represented by polymer nanoparticles, lipids, calcium phosphate, electroporation/nucleofection or biolistic delivery of DNA-coated microparticles or mRNA.
- the non-viral approach also provides transposon systems, such as the transposon system commonly known as "Sleeping Beauty” (for protocols using Sleeping Beauty transposons see for example [36].
- the viral approach provides two main types of vectors that can be used in accordance with the present invention depending on whether the DNA is integrated into chromatin of the host cell or not.
- Retroviral vectors such as those derived from gammaretroviruses or lentiviruses persist in the nucleus as integrated provirus and reproduce with cell division.
- Other types of vectors e.g. those derived from herpesviruses or adenoviruses remain in the cell in the episomal form.
- the present invention provides a vector comprising the nucleic acid molecule of any one of the above embodiments.
- the vector of any one of the above embodiments is a DNA vector, such as a plasmid or viral vector; or a non-viral vector, such as a polymer nanoparticle, lipid, calcium phosphate, DNA-coated microparticle or transposon.
- a DNA vector such as a plasmid or viral vector
- a non-viral vector such as a polymer nanoparticle, lipid, calcium phosphate, DNA-coated microparticle or transposon.
- the DNA vector is a viral vector selected from a modified virus derived from a virus selected from the group consisting of a retrovirus, lentivirus, gammavirus, adenovirus, adeno-associated virus, poxvirus, alphavirus, and herpes virus.
- the present invention provides a mammalian T cell comprising the nucleic acid molecule of any one of the above embodiments, or the DNA vector of any one of the above embodiments.
- the mammalian T cell defined above is a CD4 + helper T cell or regulatory T cell (Treg); or it may be a CD8 + effector T cell.
- the mammalian T cell defined above is expressing on its surface said aCAR.
- the mammalian T cell defined above is a human T cell.
- the present invention provides a method of preparing allogeneic or autologous aCAR T cells, the method comprising contacting T cells with the nucleic acid molecule of any one of any one of the above embodiments; or a vector as defined above, thereby preparing allogeneic or autologous aCAR T cells.
- the immune cells may be transfected with the appropriate nucleic acid molecule described herein by e.g. RNA transfection or by incorporation in a plasmid fit for replication and/or transcription in a eukaryotic cell or a viral vector.
- the vector is a viral vector selected from a modified virus derived from a virus selected from the group consisting of a retrovirus, lentivirus, gammavirus, adenovirus, adeno-associated virus, pox virus, alphavirus, and herpes virus.
- retroviral vector and an appropriate packaging line can also be used, where the capsid proteins will be functional for infecting human cells.
- amphotropic virus- producing cell lines are known, including PA12 [37], PA317 [38] and CRIP [39].
- non- ampho tropic particles can be used, such as, particles pseudotyped with VSVG, RD 114 or GAL V envelope.
- Cells can further be transduced by direct co-culture with producer cells, e.g., by the method of Bregni, et ai. [40], or culturing with viral supernatant alone or concentrated vector stocks, e.g., by the method of Xu, et al. [41]; and Hughes, et al. [42].
- the present invention provides a method of studying T cell signal transduction pathways and the effect of intracellular signaling domains on activation and ligand- dependent cell killing abilities; for example, by assessing the relative physical positioning of the different signaling and activation domains along the intracellular portion.
- the present invention provides a method of treating or preventing a disease, disorder or condition in a subject, comprising administering to said subject the mammalian T cell of any one of the above embodiments, wherein said T cell is a CD8 + effector T cell and said disease, disorder or condition is selected from a solid tumor, hematologic malignancy, melanoma, infection with a virus; or said T cell is a CD4 + regulatory T cell (Treg) and said disease, disorder or condition is manifested in excessive activity of the immune system, such as an autoimmune disease, allergy, asthma, and organ and bone marrow transplantation.
- a disease, disorder or condition in a subject, comprising administering to said subject the mammalian T cell of any one of the above embodiments, wherein said T cell is a CD8 + effector T cell and said disease, disorder or condition is selected from a solid tumor, hematologic malignancy, melanoma, infection with a virus; or said T cell is a CD4 + regulatory T
- the autoimmune disease may be selected from type 1 diabetes; rheumatoid arthritis; psoriasis; psoriatic arthritis; multiple sclerosis; systemic lupus erythematosus; inflammatory bowel disease, such as Crohn’s disease and ulcerative colitis; Addison’s disease; Graves’ disease; Sjogren’s syndrome; Hashimoto’s thyroiditis; myasthenia gravis; vasculitis; pernicious anemia; celiac disease; and atherosclerosis.
- the subject is preferably human and said mammalian Treg is allogeneic or autologous human T cell.
- allogeneic refers to tissues, organs or cells that are genetically dissimilar from, and hence immunologic ally incompatible with, a host receiving them, although from individuals of the same species.
- autologous refers to tissues, organs or cells obtained from the same individual receiving them.
- the terms "subject” or “individual” or “animal” or “patient” or “mammal,” refers to any subject, particularly a mammalian subject, for whom diagnosis, prognosis, or therapy is desired, for example, a human.
- treating refers to means of obtaining a desired physiological effect.
- the effect may be therapeutic in terms of partially or completely curing a disease and/or symptoms attributed to the disease.
- the term refers to inhibiting the disease, i.e. arresting its development; or ameliorating the disease, i.e. causing regression of the disease.
- compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients.
- the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.
- Methods of administration include, but are not limited to, parenteral, e.g., intravenous, intraperitoneal, intramuscular, subcutaneous, mucosal (e.g., oral, intranasal, buccal, vaginal, rectal, intraocular), intrathecal, topical and intradermal routes. Administration can be systemic or local. In certain embodiments, the pharmaceutical composition is adapted for oral administration.
- carrier refers to a diluent, adjuvant, excipient, or vehicle with which the active agent is administered.
- the carriers in the pharmaceutical composition may comprise a binder, such as microcrystalline cellulose, polyvinylpyrrolidone (polyvidone or povidone), gum tragacanth, gelatin, starch, lactose or lactose monohydrate; a disintegrating agent, such as alginic acid, maize starch and the like; a lubricant or surfactant, such as magnesium stearate, or sodium lauryl sulphate; and a glidant, such as colloidal silicon dioxide.
- a binder such as microcrystalline cellulose, polyvinylpyrrolidone (polyvidone or povidone), gum tragacanth, gelatin, starch, lactose or lactose monohydrate
- a disintegrating agent such as alginic acid, maize starch and the like
- a lubricant or surfactant such as
- therapeutically effective amount means an amount of the nucleic acid sequence/molecule or vector that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, i.e. treatment of a disease associated with or caused by a cell state, such as cancer.
- the amount must be effective to achieve the desired therapeutic effect as described above, depending inter alia on the type and severity of the condition to be treated and the treatment regime.
- the therapeutically effective amount is typically determined in appropriately designed clinical trials (dose range studies) and the person skilled in the art will know how to properly conduct such trials to determine the effective amount.
- an effective amount depends on a variety of factors including the affinity of the ligand to the receptor, its distribution profile within the body, a variety of pharmacological parameters such as half-life in the body, on undesired side effects, if any, and on factors such as age and gender, etc.
- articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context.
- the disclosure includes some embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process.
- the disclosure includes some embodiments in which more than one, or the entire group members are present in, employed in, or otherwise relevant to a given product or process.
- any particular embodiment of the present disclosure that falls within the prior art may be explicitly excluded from any one or more of the claims. Since such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the compositions of the disclosure (e.g., any antibiotic, therapeutic or active ingredient; any method of production; any method of use; etc.) can be excluded from any one or more claims, for any reason, whether or not related to the existence of prior art.
- B3Z is an OVA 257-264 - specific, H-2K b -restricted CTL hybridoma harboring the nuclear factor of activated T-cells (NFAT)-lacZ inducible reporter gene.
- HEK-293T is a human embryonic kidney cell line expressing T-antigen.
- M579 (579) is an HLA-A2-negative melanoma cell line and 579-A2 is a 579 transfectant expressing HLA-A2.
- B3Z is an OVA257-264-H-2Kb-specific mouse T cell hybridoma harboring the nuclear factor of activated T-cells (NFAT)-lacZ inducible reporter gene.
- PBMCs Human peripheral blood mononuclear cells
- Human lymphocytes were cultured in complete RPMI 1640 medium supplemented with 10% heat-inactivated human AB serum (Sigma-Aldrich, Saint Louis, MO) or FCS, 300 and 6,000 IU/ml recombinant human IL-2 for PBMCs and Tumor Infiltrating Leukocyte (TIL) cultures, respectively (rhIL-2; Chiron, Amsterdam, The Netherlands), 2 mmol/L L-glutamine, 1 mmol/L sodium pyruvate, 1% nonessential amino acids, 25 mM HEPES, 50 mM 2-mercaptoethanol and combined antibiotics.
- CD8 T cells were separated by positive selection using magnetic beads (BD), grown for 3- 4 days in the presence of soluble OKT3 and anti-CD28 mAbs and 1000 U/ml recombinant human IL-2 (rhIL-2, Chiron). Plasmids and gene cloning
- CAR genes were assembled via modular restriction cloning as DNA templates for in-vitro transcription in the pGEM4Z/EGFP/A64 vector [43].
- NF-KB assay we used an NF-KB- Fuciferase reporter plasmid.
- the constructs include the sequences as detailed in Table 1:
- mRNA electroporation of human T cells were linearized with Spel. Transcription and capping reactions were carried out using AmpliCap-Max T7 High Yield Message Maker Kit (Epicentre Biotechnologies, Madison, WI). The mRNA product was purified by DNase-I digestion, followed by LiCl precipitation, according to the manufacturer’s instructions. The quality of the mRNA product was assessed by agarose gel electrophoresis and concentration was determined by spectrophotometric analysis. Purified mRNA was stored at -80°C in small aliquots. mRNA electroporation of human T cells
- Electroporation was performed with ECM830 Electro Square Wave Porator (Harvard Apparatus BTX, Holliston, MA) at LV mode, single pulse, 500 V, 1 msec, or Gene Pulser Xcell (Bio-Rad Laboratories, Hercules, CA) using a square-wave pulse, 500 V, 1 msec in cold 2 mm cuvettes as follows: Stimulated CD8 T cells and TILs were washed twice with OptiMEM medium (Gibco, Grand Island, NY) and resuspended in OptiMEM at a final concentration of 3xl0 7 /ml.
- OptiMEM medium Gibco, Grand Island, NY
- pre-chilled cells For electroporation 0.1 to 0.4 ml pre-chilled cells (5 minutes on ice) were mixed with the required amount of in-vitro-transcribed mRNA. In transfection experiments involving more than one mRNA species, the appropriate amount of irrelevant mRNA was co-introduced into T cells to normalize for the total amount of exogenous mRNA.
- Chlorophenol red b-D galactopyranoside (CPRG) assay for B3Z T cell activation Following cell- or antibody-mediated activation, growth medium was removed and 100 pi of lysis buffer (9 mM MgCh, 0.125% NP40, 0.3 mM CPRG in PBS) was added to each well. 1-24 hours post-lysis the optical density (O.D.) of each well was checked using ELISA reader (at 570 nm, with 630 nm as reference). For assaying antigen- specific human CD8 T cell response, cells were washed and co-cultured in complete medium with the respective melanoma target cells at an effector-to-target ratio of 1:1 for 24 hours. IFN-g, TNF-a and GM-CSF secreted to the growth medium was monitored with commercial ELISA kits (R&D Systems Minneapolis, MN).
- NF-KB activity was measured by transient transfection of the NF-KB-Luciferase reporter plasmid to various adherent cell lines together with the particular gene under study. Twelve to forty-eight hours post-transfection luciferase activity in the cell lysate was monitored by the Luciferase Assay Systems reagent (Promega), using Infinite M200 Pro microplate reader (Tecan, Mannedorf, Switzerland). Co-culture experiments
- T cells and melanoma target cells were co-cultured for 18 hours in triplicates at an effector-to-target ratio of 1:1 for B3Z and 3:1 for human CD8 T cells.
- T cells were subjected to flow cytometry analysis using FACSCalibur (BD).
- FACSCalibur FACSCalibur
- cytokine secretion growth medium was analyzed with commercial ELISA kits.
- CD8 T cells and melanoma target cells were co-cultured as described above for the cytokine ELISA. After 18 hours of co-culture cells with growth medium were transferred to a FACS tube, centrifuged for 7 min at 1,500 RPM and the supernatant was assayed for target cell killing using a commercial kit for the lactate dehydrogenase (LDH) cell cytotoxicity assay (BioVision, Milpitas, CA).
- LDH lactate dehydrogenase
- CD28 transmembrane domain was reported to support better surface expression than 4- IBB [44], we decided to similarly assess CD40, CD28 and 4- IBB.
- the two 3 rd generation CARs comprise the CD28 transmembrane and intracellular portion followed by either CD40 or 4- IBB intracellular domain.
- the functional properties conferred on human T cells were compared by the two pairs of 2nd and 3rd generation CARs following antigenic stimulus.
- CD8 T cells from peripheral blood samples of two HLA-A2(-) healthy donors.
- mild surface expression following electroporation of CD8 T cells of the two donors was demonstrated (Not shown).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
A nucleic acid molecule encoding an activating chimeric antigen receptor (aCAR) comprising at least one signal transduction element derived from CD40 is provided.
Description
CHIMERIC ANTIGEN RECEPTOR COMPRISING CD40 CYTOPLASMIC DOMAIN AND USES THEREOF
CROSS REFERENCE TO RELATED APPLICATIONS
The present application claims the benefit of priority to U.S. Provisional Patent Application No. 62/898,704 filed September 11, 2019, the contents of which are incorporated by reference herein in their entirety.
FIELD OF THE INVENTION
The present invention relates in general to activating chimeric antigen receptors (aCARs) and their use in immunotherapy of cancer.
BACKGROUND OF THE INVENTION
In the late 1980s and early 1990s, double- and single-chain CARs were introduced as new genetic means to redirect T cells at will, paving the way to the entire field of CAR-T cell therapy of cancer [1,2]. In 2017 the first CAR-T products were approved by the FDA for the treatment of B cell acute lymphoblastic leukemia and non-Hodgkin lymphoma and approximately four hundred clinical trials are currently examining CAR therapy in a wide range of hematologic malignancies and solid tumors (see our review [3], [4,5] and https://clinicaltrials.gov/).
The low response rates observed in solid tumors underscore the need in enhancing the tumoricidal activity of CAR-T cells for improving their therapeutic efficacy. Aside from the apparent lack of suitable tumor antigens, CAR-T cells face major obstacles posed by both extrinsic and intrinsic factors. Extrinsically, the transferred T cells are confronted by the resilient tumor microenvironment, which often recruits immune suppressor cells, including regulatory T cells (Tregs), myeloid derived suppressor cells and tumor-associated macrophages and exploits diverse evasion mechanisms to prevent T cell access and avoid an immunological attack [6]. Prominent among the intrinsic hurdles are the limited persistence and proliferative capacity of the transfused T cells, their functional exhaustion following lengthy ex-vivo propagation, the acquisition of an unfavorable terminal effector T cell differentiation state, antigen-induced cell death (AICD) as a result of prolonged exposure to antigen and the uncontrolled production of tonic signaling, which may impede T cell reactivity and survival [7,8].
In attempt to overcome these limitations, a huge amount of effort is put in recent years into optimizing the signaling moieties incorporated into the intracellular portion of 2nd and 3rd generation CARs, which largely govern the clinical outcome of CAR-T cell therapy. A variety of
costimulatory signaling elements and their combinations, capable of augmenting diverse aspects of T cell function and lifespan, have been explored along this route, including CD28, 4- IBB, 0X40, ICOS, CD27, CD244, CD80 and 4-1BBL [8-10]. The most widely explored of these are undoubtedly CD28 and 4- IBB.
Engagement of the key costimulatory receptor CD28 with B7 proteins on antigen- presenting cells (APCs) is mandatory for priming of naive T cells, signaling enhanced TCR- induced proliferation, differentiation and acquisition of diverse effector functions [11-13]. 4-1BB (CD137), a member of the tumor necrosis factor receptor (TNFR) family is expressed on activated human T cells. The TNFR family also includes 0X40 and CD27, whose signaling elements have similarly been assessed in advanced CAR designs. The cytosolic portions of these TNFRs bear structural similarities and they all signal through adaptor TNFR-associated factor (TRAF) proteins via the NFKB, p38 MAPK or JNK/SAPK pathways [14].
4- IBB ligation by cognate ligand or soluble agonists promotes T cell survival by counteracting apoptosis, induces cell division, augments Thl cytokine production, protects T cells from AICD, drives memory formation and confers resistance to Treg suppression [11,15]. Not surprisingly, the signaling domains of CD28 and 4- IBB have been extensively explored as the costimulatory components of 2nd and 3rd generation CARs.
Numerous studies of 2nd generation CARs have revealed marked differences in the effects exerted by the CD28 and 4- IBB signaling domains, reflecting their distinct physiological roles. [8,11]. For example, CD28 was shown to support the rapid acquisition of effector functions and tumor eradication capacity but only limited persistence, both in apparent contrast to 4- IBB (e.g., [10,16,17]). While CD28 mostly induces CAR-T cell differentiation into the effector-memory type, 4- IBB preferentially drives central memory formation [18]. Surprisingly, engrafting these two costimulatory domains in tandem to create 3rd generation CARs does not necessarily result in improved therapeutic activity in-vivo (see [8] for a recent review). Moreover, it is becoming increasingly clear that not all physiological functions of native CD28 and 4- IBB are preserved in CARs [11]. Critically, contradicting reports on functional outcomes may merely reflect different experimental contexts. For example, 4-lBB-mediated tonic signaling was reported to exert either positive [9] or negative [19] effects on CAR-T cell survival and functionality.
Thus, there still remains an unmet need for improved aCARS for use in immunotherapy of cancer.
SUMMARY OF THE INVENTION
In one aspect, the present invention provides a nucleic acid molecule comprising a nucleotide sequence encoding an activating chimeric antigen receptor (aCAR) comprising: (i) an
extracellular binding domain capable of binding to an antigen; (ii) a transmembrane domain; (iii) an intracellular domain; and (iv) a flexible hinge or stalk domain linking the extracellular binding domain and the transmembrane domain, said flexible hinge or stalk domain comprising a cysteine residue capable of forming a cysteine bridge thereby forming an aCAR homodimer, wherein said intracellular domain is selected from:
(a) an intracellular domain comprising at least one signal transduction element derived from CD40 and a second amino acid sequence comprising at least one signal transduction element derived from an FcR gamma (g) chain, CD3 zeta (z) chain, or CD3 eta (h) chain, and lacking a MyD88 polypeptide, 2A self-cleaving peptide or a dimerizing domain;
(b) an intracellular domain comprising at least one signal transduction element derived from CD40 and a third amino acid sequence comprising at least one signal transduction element derived from CD28 or 4- IBB; and
(c) an intracellular domain comprising a first amino acid sequence comprising at least one signal transduction element derived from CD40, a second amino acid sequence comprising at least one signal transduction element derived from an FcR gamma (g) chain, CD3 zeta (z) chain, or CD3 eta (h) chain and a third amino acid sequence comprising at least one signal transduction element derived from CD28; and
(d) an intracellular domain comprising a first amino acid sequence comprising at least one signal transduction element derived from CD40 and lacking a MyD88 polypeptide or a truncated MyD88 polypeptide lacking the Toll/IL-1 receptor domain (TIR) domain and may alternatively or further lack a myristoylation-targeting sequence or a dimerizing domain, such as an FKBP12v36 domain.
In another aspect, the present invention provides a composition comprising the nucleic acid molecule of any one of any one of the above embodiments.
In an additional aspect, the present invention provides a vector comprising the nucleic acid molecule of any one of the above embodiments.
In yet another aspect, the present invention provides a mammalian T cell comprising the nucleic acid molecule of any one of the above embodiments, or the DNA vector of any one of the above embodiments.
In yet an additional aspect, the present invention provides a method of preparing allogeneic or autologous aCAR T cells, the method comprising contacting T cells with the nucleic acid molecule of any one of any one of the above embodiments; or a DNA vector as defined above, thereby preparing allogeneic or autologous aCAR T cells.
In a further aspect, the present invention provides a method of treating or preventing a disease, disorder or condition in a subject, comprising administering to said subject the mammalian T cell of any one of the above embodiments, wherein said T cell is a CD8+ effector T cell and said disease, disorder or condition is selected from a solid tumor, hematologic malignancy, melanoma, infection with a virus; or said T cell is a CD4+ regulatory T cell (Treg) and said disease, disorder or condition is manifested in excessive activity of the immune system, such as an autoimmune disease, allergy, asthma, and organ and bone marrow transplantation.
BRIEF DESCRIPTION OF THE DRAWINGS
The patent or application file contains at least one drawing executed in color or grayscale. Copies of this patent or patent application publication with color or grayscale drawings will be provided by the Office upon request and payment of necessary fee.
Fig. 1 shows a schematic representation of the eight CARs, where “Li” refers to the first flexible peptide linker of the single chain variable fragment, and “T” refers to the Myc tag.
Fig. 2 shows CAR surface expression. K562 cells were transfected by electroporation with 10 qg of each of the indicated mRNAs. Twenty-four hours later cells were subjected to flow cytometry analysis for expression of the Myc tag. Black histograms, irrelevant mRNA; grey histograms, CARs. See Fig. 1 for key to CAR names.
Figs. 3A-B shows CAR functionality. (A) Antigen- specific activity of the new CARs (see Fig. 1 for key to CAR names). B3Z T cells possessing the reporter NFAT-LacZ gene were electroporated with each of the indicated mRNAs. Seven hours post-electroporation cells were incubated at 1:1 ratio with 579 melanoma cells (checkered), 579-A2 melanoma cells (black) or no cells (white), and 24 hours later cell lysates were subjected to the colorimetric CPRG assay. (B) Activation of the NF-KB signaling pathway. HEK293T cells were transfected with the NF-KB- luciferase reporter plasmid and 24 hours later with mRNA encoding each of the indicated constructs. Histograms show relative luminescence units (RLU) in cell lysates. 201, activation by anti-CD3 mAh; Irr., irrelevant mRNA; P.C., positive control, constitutively active CD40 (caCD40, (7)). Results are representative of three independent experiments.
Figs. 4A-F show antigen- specific activation of human CD8 T cells. CD8 T cells of Donor I (A-C) and Donor II (D-F) that were electroporated with CAR mRNA and subjected to expression and function analyses (see Fig. 1 for key to CAR names). ELISA for the secretion of pro- inflammatory cytokines IFN-g (A, D), TNF-a (B, E), GM-CSF (C, F).
Figs. 5A-B show LDH assay for target cell (579 melanoma cells (white) or 579-A2 melanoma cells (black)) killing by cells obtained from Donor I (A) and Donor II (B). Results shown in ‘A’ represent three, and in ‘B’ two, independent experiments, all performed separately
for CD8 T cells of each of the two donors.
DETAILED DESCRIPTION OF THE INVENTION
CD40 is a member of the TNFR family and is mainly expressed by professional APCs. A number of studies suggest that CD40 is functionally expressed also by T cells. The direct T cell stimulatory capacity of CD40 was manifested in a wide range of effects including differentiation, memory formation, improvement of functional avidity, upregulation of anti-apoptotic signals and decreasing pro-apoptotic ones, rescue from exhaustion and acquisition of resistance to Treg- mediated suppression [20-22]. Yet, other studies failed to confirm these observations and the immunological role played by T cell-expressed CD40 under physiological conditions is still elusive. Nevertheless, recently, the potent costimulatory capacity of the CD40 signaling domain has successfully been recruited to native unmodified T cells [23-25]. In contrast, others have found that CD40 signaling domains are inactive in the context of aCARs unless they are conjugated with self-assembly and myD88 domains [26-28].
The inventors of the present invention have constructed a series of new anti-HLA-A2 CARs harboring either the intracellular signaling domain of CD40 or of 4-1BB, with or without the intracellular signaling domain of CD28, and examined these CARs in mRNA-electroporated human CD8 T cells. Schematic presentation of the series of constructs examined is depicted in Fig. 1 and detailed in Table 1. It was unexpectedly found that the mere incorporation of the CD40 signaling domain in the intracellular portion of the different CARs led to spontaneous activation of the NF-KB signaling pathway, which was consistently higher than that induced by the corresponding CARs harboring the 4-1BB signaling domain (Fig. 2B). Furthermore, although not even traces of CD40 expression could be detected in any of the human T cells previously tested by us, the CD40 signaling domain was fully potent in these T cells, as manifested by the introduction of either caCD40 or of native CD40, followed by CD40L stimulation [24].
In one aspect, the present invention a nucleic acid molecule comprising a nucleotide sequence encoding an activating chimeric antigen receptor (aCAR) comprising: (i) an extracellular binding domain capable of binding to an antigen; (ii) a transmembrane domain; (iii) an intracellular domain; and (iv) a flexible hinge or stalk domain linking the extracellular binding domain and the transmembrane domain, said flexible hinge or stalk domain comprising a cysteine residue capable of forming a cysteine bridge thereby forming an aCAR homodimer, wherein said intracellular domain is selected from:
(a) an intracellular domain comprising at least one signal transduction element derived from CD40 and a second amino acid sequence comprising at least one signal transduction element
derived from an FcR gamma (g) chain, CD3 zeta (z) chain, or CD3 eta (h) chain, and lacking a MyD88 polypeptide, 2A self-cleaving peptide or a dimerizing domain;
(b) an intracellular domain comprising at least one signal transduction element derived from CD40 and a third amino acid sequence comprising at least one signal transduction element derived from CD28 or 4- IBB; and
(c) an intracellular domain comprising a first amino acid sequence comprising at least one signal transduction element derived from CD40, a second amino acid sequence comprising at least one signal transduction element derived from an FcR gamma (g) chain, CD3 zeta (z) chain, or CD3 eta (h) chain and a third amino acid sequence comprising at least one signal transduction element derived from CD28; and
(d) an intracellular domain comprising a first amino acid sequence comprising at least one signal transduction element derived from CD40 and lacking a MyD88 polypeptide or a truncated MyD88 polypeptide lacking the Toll/IL-1 receptor domain (TIR) domain and may alternatively or further lack a myristoylation-targeting sequence or a dimerizing domain, such as an FKBP12v36 domain [29].
The signal transduction element derived from CD40 may be a tumor necrosis factor receptor (TNFR)-associated factor (TRAF) -binding domain, e.g. TRAF2, TRAF3, TRAF5 and TRAF6 binding domain. TRAF2, 3 and 5 usually have overlapping binding motifs, whereas TRAF6 has a distinct interacting motif on these receptors, and TRAF1 binds to the CD40 signal transduction element via TRAF2 [30].
In certain embodiments, the signal transduction element derived from the FcR gamma (g) chain, CD3 zeta (z) chain, or CD3 eta (h) chain is an immunoreceptor tyrosine-based activation motif (IT AM). This motif contains a tyrosine separated from a leucine or isoleucine by any two other amino acids, giving the signature YxxL/I. Two of these signatures are typically separated by between 6 and 8 amino acids in the cytoplasmic tail of the molecule (YxxL/Ix(6-8)YxxL/I).
A T cell or cell population comprising a T cell expressing the aCAR of the present invention has an increased cytotoxic activity against a cell having the target antigen on the surface, as compared to a T cell or cell population comprising a T cell expressing an aCAR whose intracellular domain consists of an intracellular domain of CD28 and Oϋ3z, 4-1BB and Oϋ3z, or CD28 and 4- IBB.
In certain embodiments, the extracellular binding domain comprises (i) an antibody, derivative or fragment thereof, such as a humanized antibody; a human antibody; a functional fragment of an antibody; a single-domain antibody, such as a Nanobody; a recombinant antibody; and a single chain variable fragment (ScFv); (ii) an antibody mimetic, such as an affibody
molecule; an affilin; an affimer; an affitin; an alphabody; an anticalin; an avimer; a DARPin; a fynomer; a Kunitz domain peptide; and a monobody; or (iii) an ap tamer.
In particular embodiments, the extracellular binding domain comprises an ScFv. In certain embodiments, the ScFv comprises a Variable Light chain (VL) and a Variable Heavy chain (VH) linked by a first flexible peptide linker, e.g. of SEQ ID NO: 12.
In a certain embodiment, the transmembrane domain of the aCAR is selected from the transmembrane domain of CD28, CD40, CD3- z, TLR1, TLR2, TLR4, TLR5, TLR9, and Fc receptor.
In certain embodiments, the transmembrane domain is the CD28 transmembrane domain, e.g. of SEQ ID NO: 16.
In certain embodiments, the transmembrane domain is the CD40 transmembrane domain, e.g. of SEQ ID NO: 22.
In certain embodiments, the first amino acid sequence is the complete intracellular domain of CD40, e.g. of SEQ ID NO: 17.
In certain embodiments, the at least one signal transduction element of the second amino acid sequence is derived from an FcRy chain.
In certain embodiments, the second amino acid sequence is the complete intracellular domain of an FcRy chain, e.g. of SEQ ID NO: 18.
In certain embodiments, the third amino acid sequence is the complete intracellular domain of CD28, e.g. of SEQ ID NO: 20.
In certain embodiments, the flexible hinge or stalk comprises a polypeptide selected from a hinge region of CD8a or Oϋ8b. The sequence and structure of these hinge domains are well- characterized (e.g. Wong et al. [31]). The flexible hinge or stalk may further by selected from a hinge region of a heavy chain of IgG, and a hinge region of a heavy chain of IgD.
In certain embodiments, the flexible hinge domain is the hinge domain of CD8a, e.g. a complete flexible hinge domain, optionally altered by the addition of two Ser residues at its C- terminus (to form an Xhol restriction site), such as in the sequence of SEQ ID NO: 15.
In particular embodiments, the nucleic acid molecule of any one of the above embodiments comprises a nucleotide sequence encoding an aCAR comprising an extracellular binding domain comprising (i) an antibody, derivative or fragment thereof, such as a humanized antibody; a human antibody; a functional fragment of an antibody; a single-domain antibody, such as a Nanobody; a recombinant antibody; and a single chain variable fragment (ScFv); (ii) an antibody mimetic, such as an affibody molecule; an affilin; an affimer; an affitin; an alphabody; an anticalin; an avimer; a DARPin; a fynomer; a Kunitz domain peptide; and a monobody; or (iii) an aptamer; said
transmembrane domain is selected from the transmembrane domain of CD28, CD40, CDS-z, TLR1, TLR2, TLR4, TLR5, TLR9, and Fc receptor; the first amino acid sequence is the complete intracellular domain of CD40, e.g. of SEQ ID NO: 17; the at least one signal transduction element of the second amino acid sequence is derived from an FcRy chain; the third amino acid sequence, when present, is the complete intracellular domain of CD28, e.g. of SEQ ID NO: 20; and the flexible hinge comprises a polypeptide selected from a hinge region of CD8a, Oϋ8b, a hinge region of a heavy chain of IgG, and a hinge region of a heavy chain of IgD.
In certain embodiments, the aCAR of the previous embodiment comprises an extracellular binding domain comprising an ScFv; the transmembrane domain is the transmembrane domain of CD28 e.g. of SEQ ID NO: 16; the second amino acid sequence is the complete intracellular domain of an FcRy chain, e.g. of SEQ ID NO: 18; and the flexible hinge domain is the flexible hinge domain of CD8a.
In certain embodiments, the intracellular domain of any one of the above aCARs comprises or essentially consists of a tandem arrangement of the complete intracellular domains of CD40- FcRy.
In certain embodiments, the intracellular domain of any one of the above aCARs comprises or essentially consists of a tandem arrangement of the complete intracellular domains of CD28- CD40-FcRy, wherein the intracellular domain of CD28 is optionally linked to the intracellular domain of CD40 via a short oligopeptide linker.
Or in other words, the tandem arrangement is selected from a polypeptide comprising the complete intracellular domains of [N-terminus-CD28]-[optional short oligopeptide linker] -[CD40- FcRy-C-terminus]; and [N-terminus- CD40]-[FcRy-C-terminus]. The order of appearance of the different domains from N- to C-terminus can be different, e.g. [N-terminus-CD40]-[optional short oligopeptide linker]-[CD28-FcRy-C-terminus] .
In certain embodiments, the intracellular domain of any one of the above aCARs comprises or essentially consists of the complete intracellular domains of 4- IBB, CD40, and FcRy. For example, the aCAR may comprise an ScFv; the transmembrane domain of CD28; the complete intracellular domain of CD40, the complete intracellular domain of 4- IBB, the complete intracellular domain of an FcRy chain; and the flexible hinge domain of CD8a.
Flexible peptide linkers are well-known in the art. Empirical linkers designed by researchers are generally classified into three categories according to their structures: flexible linkers, rigid linkers, and in vivo cleavable linkers as defined e.g. in [32-34], each one of which is incorporated by reference as if fully disclosed herein.
The structure of the flexible short oligopeptide linker is selected from any one of the linkers disclosed in [32-34]. In principle, to provide flexibility, the linkers are generally composed of small, non-polar (e.g. Gly) or polar (e.g. Ser or Thr) amino acids, such an underlying sequence of alternating Gly and Ser residues. Solubility of the linker and associated signal transduction elements may be enhanced by including charged residues; e.g. two positively charged residues (Lys) and one negatively charged residue (Glu). The linker may vary from 2 to 31 amino acids, optimized for each condition so that the linker does not impose any constraints on the conformation or interactions of the linked partners in lengths.
In a certain embodiment, the flexible short oligopeptide linker has the amino acid sequence Gly-Gly-Gly
In certain embodiments, the intracellular domain comprises or essentially consists of a tandem arrangement of the complete intracellular domains of [CD28]-[ short oligopeptide linker]- [CD40]-[FcRy] (from N- to C-terminus). (28-40-g)
In certain embodiments, the aCAR comprises a tandem arrangement of (from N- to C- terminus) [ScFv]-[hinge region of CD8a-CD28 transmembrane domain] -[intracellular domain essentially consisting of a tandem arrangement of the complete intracellular domains of CD40- FcRyj. (40-g)
In certain embodiments, the aCAR comprises a tandem arrangement of (from N- to C- terminus) [ScFv]-[hinge region of CD8a-CD28 transmembrane domain] -[intracellular domain essentially consisting of a tandem arrangement of the complete intracellular domains of CD28- CD40-FcRy], wherein the intracellular domain of CD28 is optionally linked to the intracellular domain of CD40 via a linker.
In certain embodiments, the DNA or amino-acid sequence of each one of the different domains of the aCAR is the human sequence.
In certain embodiments, the aCAR, excluding the extracellular binding domain, comprises the combined amino acid sequences of SEQ ID NOs: 15+16+20+Gly-Gly-Gly+17+18; or 15+16+17+18.
Non-limiting examples of complete sequences of DNA encoding aCARs of the present invention are set forth in SEQ ID NOs: 25, 27, 29, 31, 33, 35, 37, and 39; and non-limiting examples of complete amino acid sequences of aCARs of the present invention are set forth in 26, 28, 30, 32, 34, 36, 38, and 40. It should be made clear that these are examples disclosed for the sole purpose of teaching one specific way of making the present invention, which can be easily adapted by a person skilled in the art to fulfill different experimental demands, e.g. by the
introduction or abolishment of enzyme restriction sites or short flexible oligopeptide linkers as required, or by synonymous changes in the DNA sequence to improve expression.
The different domains, and full sequence, of the aCARs defined above may have amino acid sequences that have at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85 %, at least 90 %, or at least 95, 96, 97, 98, or 99% identity to the sequences defined in SEQ ID NO: 15, 16, 17, 18, 20, 26, 28, 30, 32, 34, 36, 38, and 40 and other combined sequences recited above, respectively, as long as the aCAR is active, i.e. is capable of activating a T cell in an antigen-dependent manner.
The nucleotide sequences encoding the various domains of the aCAR defined above comprise ah redundant nucleotide sequences encoding the amino acid sequences of these domains as well as similar sequences encoding for active aCARs. Thus, the nucleotide sequences encoding for amino acid sequences of SEQ ID NO: 15, 16, 17, 18, 20, 26, 28, 30, 32, 34, 36, 38, and 40 are as set forth in SEQ ID NO: 6, 7, 8, 9, 20, 25, 27, 29, 31, 33, 35, 37, and 39, respectively; or any other redundant sequence encoding for identical amino acid sequences. Furthermore, the nucleotide sequences may have at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85 %, at least 90 %, or at least 95, 96, 97, 98, or 99% identity to the sequences defined in SEQ ID NO: 6, 7, 8, 9, 19, 25, 27, 29, 31, 33, 35, 37, and 39, and the nucleotide sequences encoding for other combined amino acid sequences recited above, respectively, as long as the encoded aCAR is active, i.e. is capable of activating a T cell in an antigen-dependent manner.
In certain embodiments, the intracellular domain of (c) or (d) of any one of the above embodiments lacks MyD88 polypeptide or a truncated MyD88 polypeptide lacking the Toh/IL-1 receptor domain (TIR) domain and may alternatively or further lack a myristoylation-targeting sequence or a dimerizing domain, such as an FKBP12v36 domain.
In certain embodiments, the intracellular domain of (a) (b), (c) or (d) of any one of the above embodiments lacks a self-cleaving peptide, such as 2A self-cleaving peptide including any one of P2A, E2A, F2A and T2A.
In another aspect, the present invention provides a composition comprising the nucleic acid molecule of any one of any one of the above embodiments.
Matuskova and Durinikova [35] teach that there are two systems for the delivery of transgenes into a cell - viral and non-viral. The non- viral approaches are represented by polymer nanoparticles, lipids, calcium phosphate, electroporation/nucleofection or biolistic delivery of DNA-coated microparticles or mRNA. The non-viral approach also provides transposon systems, such as the transposon system commonly known as "Sleeping Beauty" (for protocols using Sleeping Beauty transposons see for example [36].
The viral approach provides two main types of vectors that can be used in accordance with the present invention depending on whether the DNA is integrated into chromatin of the host cell or not. Retroviral vectors such as those derived from gammaretroviruses or lentiviruses persist in the nucleus as integrated provirus and reproduce with cell division. Other types of vectors (e.g. those derived from herpesviruses or adenoviruses) remain in the cell in the episomal form.
In an additional aspect, the present invention provides a vector comprising the nucleic acid molecule of any one of the above embodiments.
In certain embodiments, the vector of any one of the above embodiments is a DNA vector, such as a plasmid or viral vector; or a non-viral vector, such as a polymer nanoparticle, lipid, calcium phosphate, DNA-coated microparticle or transposon.
In certain embodiments, the DNA vector is a viral vector selected from a modified virus derived from a virus selected from the group consisting of a retrovirus, lentivirus, gammavirus, adenovirus, adeno-associated virus, poxvirus, alphavirus, and herpes virus.
In yet another aspect, the present invention provides a mammalian T cell comprising the nucleic acid molecule of any one of the above embodiments, or the DNA vector of any one of the above embodiments.
In certain embodiments, the mammalian T cell defined above is a CD4+ helper T cell or regulatory T cell (Treg); or it may be a CD8+ effector T cell.
In certain embodiments, the mammalian T cell defined above is expressing on its surface said aCAR.
In certain embodiments, the mammalian T cell defined above is a human T cell.
In yet an additional aspect, the present invention provides a method of preparing allogeneic or autologous aCAR T cells, the method comprising contacting T cells with the nucleic acid molecule of any one of any one of the above embodiments; or a vector as defined above, thereby preparing allogeneic or autologous aCAR T cells.
The immune cells may be transfected with the appropriate nucleic acid molecule described herein by e.g. RNA transfection or by incorporation in a plasmid fit for replication and/or transcription in a eukaryotic cell or a viral vector. In certain embodiments, the vector is a viral vector selected from a modified virus derived from a virus selected from the group consisting of a retrovirus, lentivirus, gammavirus, adenovirus, adeno-associated virus, pox virus, alphavirus, and herpes virus.
Combinations of retroviral vector and an appropriate packaging line can also be used, where the capsid proteins will be functional for infecting human cells. Several amphotropic virus- producing cell lines are known, including PA12 [37], PA317 [38] and CRIP [39]. Alternatively,
non- ampho tropic particles can be used, such as, particles pseudotyped with VSVG, RD 114 or GAL V envelope. Cells can further be transduced by direct co-culture with producer cells, e.g., by the method of Bregni, et ai. [40], or culturing with viral supernatant alone or concentrated vector stocks, e.g., by the method of Xu, et al. [41]; and Hughes, et al. [42].
In a further aspect, the present invention provides a method of studying T cell signal transduction pathways and the effect of intracellular signaling domains on activation and ligand- dependent cell killing abilities; for example, by assessing the relative physical positioning of the different signaling and activation domains along the intracellular portion.
In a further aspect, the present invention provides a method of treating or preventing a disease, disorder or condition in a subject, comprising administering to said subject the mammalian T cell of any one of the above embodiments, wherein said T cell is a CD8+ effector T cell and said disease, disorder or condition is selected from a solid tumor, hematologic malignancy, melanoma, infection with a virus; or said T cell is a CD4+ regulatory T cell (Treg) and said disease, disorder or condition is manifested in excessive activity of the immune system, such as an autoimmune disease, allergy, asthma, and organ and bone marrow transplantation.
For example, the autoimmune disease may be selected from type 1 diabetes; rheumatoid arthritis; psoriasis; psoriatic arthritis; multiple sclerosis; systemic lupus erythematosus; inflammatory bowel disease, such as Crohn’s disease and ulcerative colitis; Addison’s disease; Graves’ disease; Sjogren’s syndrome; Hashimoto’s thyroiditis; myasthenia gravis; vasculitis; pernicious anemia; celiac disease; and atherosclerosis.
In certain embodiments, the subject is preferably human and said mammalian Treg is allogeneic or autologous human T cell.
Definitions
The term “allogeneic” as used herein refers to tissues, organs or cells that are genetically dissimilar from, and hence immunologic ally incompatible with, a host receiving them, although from individuals of the same species.
The term “autologous” as used herein refers to tissues, organs or cells obtained from the same individual receiving them.
As used herein, the terms "subject" or "individual" or "animal" or "patient" or "mammal," refers to any subject, particularly a mammalian subject, for whom diagnosis, prognosis, or therapy is desired, for example, a human.
The term “treating” as used herein refers to means of obtaining a desired physiological effect. The effect may be therapeutic in terms of partially or completely curing a disease and/or symptoms attributed to the disease. The term refers to inhibiting the disease, i.e. arresting its
development; or ameliorating the disease, i.e. causing regression of the disease.
Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.
Methods of administration include, but are not limited to, parenteral, e.g., intravenous, intraperitoneal, intramuscular, subcutaneous, mucosal (e.g., oral, intranasal, buccal, vaginal, rectal, intraocular), intrathecal, topical and intradermal routes. Administration can be systemic or local. In certain embodiments, the pharmaceutical composition is adapted for oral administration.
The term “carrier” refers to a diluent, adjuvant, excipient, or vehicle with which the active agent is administered. The carriers in the pharmaceutical composition may comprise a binder, such as microcrystalline cellulose, polyvinylpyrrolidone (polyvidone or povidone), gum tragacanth, gelatin, starch, lactose or lactose monohydrate; a disintegrating agent, such as alginic acid, maize starch and the like; a lubricant or surfactant, such as magnesium stearate, or sodium lauryl sulphate; and a glidant, such as colloidal silicon dioxide.
The following exemplification of carriers, modes of administration, dosage forms, etc., are listed as known possibilities from which the carriers, modes of administration, dosage forms, etc., may be selected for use with the present invention. Those of ordinary skill in the art will understand, however, that any given formulation and mode of administration selected should first be tested to determine that it achieves the desired results.
The term "therapeutically effective amount" as used herein means an amount of the nucleic acid sequence/molecule or vector that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, i.e. treatment of a disease associated with or caused by a cell state, such as cancer. The amount must be effective to achieve the desired therapeutic effect as described above, depending inter alia on the type and severity of the condition to be treated and the treatment regime. The therapeutically effective amount is typically determined in appropriately designed clinical trials (dose range studies) and the person skilled in the art will know how to properly conduct such trials to determine the effective amount. As generally known, an effective amount depends on a variety of factors including the affinity of the ligand to the receptor, its distribution profile within the body, a variety of pharmacological parameters such as half-life in the body, on undesired side effects, if any, and on factors such as age and gender, etc.
The transition phrase "consisting essentially of" or "essentially consisting of", when referring to an amino acid or nucleic acid sequence, refers to the a sequence that includes the listed sequence and is open to present or absent unlisted sequences that do not materially affect the basic
and novel properties of the protein itself or the protein encoded by the nucleic acid sequence.
Unless otherwise indicated, all numbers used in this specification are to be understood as being modified in all instances by the term "about". Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification are approximations that may vary by up to plus or minus 10% depending upon the desired properties to be obtained by the present invention.
EQUIVALENTS AND SCOPE
Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the certain embodiments in accordance with the disclosure described herein. The scope of the present disclosure is not intended to be limited to the above Description, but rather is as set forth in the appended claims.
In the claims, articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The disclosure includes some embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The disclosure includes some embodiments in which more than one, or the entire group members are present in, employed in, or otherwise relevant to a given product or process.
It is also noted that the term “comprising” is intended to be open and permits but does not require the inclusion of additional elements or steps. When the term “comprising” is used herein, the term “consisting of’ is thus also encompassed and disclosed.
Where ranges are given, endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or subrange within the stated ranges in different embodiments of the disclosure, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.
In addition, it is to be understood that any particular embodiment of the present disclosure that falls within the prior art may be explicitly excluded from any one or more of the claims. Since such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the compositions of the disclosure (e.g., any antibiotic, therapeutic or active ingredient; any method of production; any method of use; etc.) can be excluded from any one or more claims, for any
reason, whether or not related to the existence of prior art.
It is to be understood that the words which have been used are words of description rather than limitation, and that changes may be made within the purview of the appended claims without departing from the true scope and spirit of the disclosure in its broader aspects.
While the present disclosure has been described at some length and with some particularity with respect to the several described embodiments, it is not intended that it should be limited to any such particulars or embodiments or any particular embodiment, but it is to be construed with references to the appended claims so as to provide the broadest possible interpretation of such claims in view of the prior art and, therefore, to effectively encompass the intended scope of the disclosure.
The invention will now be illustrated by the following non-limiting Examples.
EXAMPLES
Materials and Methods
Cell lines
B3Z is an OVA257-264- specific, H-2Kb-restricted CTL hybridoma harboring the nuclear factor of activated T-cells (NFAT)-lacZ inducible reporter gene. HEK-293T is a human embryonic kidney cell line expressing T-antigen.
M579 (579) is an HLA-A2-negative melanoma cell line and 579-A2 is a 579 transfectant expressing HLA-A2. B3Z is an OVA257-264-H-2Kb-specific mouse T cell hybridoma harboring the nuclear factor of activated T-cells (NFAT)-lacZ inducible reporter gene.
Human T cell culture
Human peripheral blood mononuclear cells (PBMCs) were obtained from the MDA National Blood Services (Tel-Hashomer, Israel).
Human lymphocytes were cultured in complete RPMI 1640 medium supplemented with 10% heat-inactivated human AB serum (Sigma-Aldrich, Saint Louis, MO) or FCS, 300 and 6,000 IU/ml recombinant human IL-2 for PBMCs and Tumor Infiltrating Leukocyte (TIL) cultures, respectively (rhIL-2; Chiron, Amsterdam, The Netherlands), 2 mmol/L L-glutamine, 1 mmol/L sodium pyruvate, 1% nonessential amino acids, 25 mM HEPES, 50 mM 2-mercaptoethanol and combined antibiotics.
CD8 T cells were separated by positive selection using magnetic beads (BD), grown for 3- 4 days in the presence of soluble OKT3 and anti-CD28 mAbs and 1000 U/ml recombinant human IL-2 (rhIL-2, Chiron).
Plasmids and gene cloning
CAR genes were assembled via modular restriction cloning as DNA templates for in-vitro transcription in the pGEM4Z/EGFP/A64 vector [43]. For the NF-KB assay we used an NF-KB- Fuciferase reporter plasmid. The constructs include the sequences as detailed in Table 1:
In-vitro transcription of mRNA
Template plasmids were linearized with Spel. Transcription and capping reactions were carried out using AmpliCap-Max T7 High Yield Message Maker Kit (Epicentre Biotechnologies, Madison, WI). The mRNA product was purified by DNase-I digestion, followed by LiCl precipitation, according to the manufacturer’s instructions. The quality of the mRNA product was
assessed by agarose gel electrophoresis and concentration was determined by spectrophotometric analysis. Purified mRNA was stored at -80°C in small aliquots. mRNA electroporation of human T cells
Electroporation was performed with ECM830 Electro Square Wave Porator (Harvard Apparatus BTX, Holliston, MA) at LV mode, single pulse, 500 V, 1 msec, or Gene Pulser Xcell (Bio-Rad Laboratories, Hercules, CA) using a square-wave pulse, 500 V, 1 msec in cold 2 mm cuvettes as follows: Stimulated CD8 T cells and TILs were washed twice with OptiMEM medium (Gibco, Grand Island, NY) and resuspended in OptiMEM at a final concentration of 3xl07/ml. For electroporation 0.1 to 0.4 ml pre-chilled cells (5 minutes on ice) were mixed with the required amount of in-vitro-transcribed mRNA. In transfection experiments involving more than one mRNA species, the appropriate amount of irrelevant mRNA was co-introduced into T cells to normalize for the total amount of exogenous mRNA.
Flow cytometry analysis
Cells were harvested, washed once with cold FACS buffer (PBS with 1% FCS and 0.1% sodium azide) and incubated for 30 minutes at 4°C in the dark with the respective Ab-conjugate at concentration recommended by the manufacturer. Cells were washed again with 4 ml FACS buffer, resuspended in 0.3 ml PBS with 0.1% sodium azide and subjected to flow cytometry using FACSCalibur or FACSAria II (Becton Dickinson, San Jose, CA). Data were analyzed by LSRII (BD) and FCSexpress (DeNovo Software, Los Angeles, CA).
T cell activation assays
Chlorophenol red b-D galactopyranoside (CPRG) assay for B3Z T cell activation: Following cell- or antibody-mediated activation, growth medium was removed and 100 pi of lysis buffer (9 mM MgCh, 0.125% NP40, 0.3 mM CPRG in PBS) was added to each well. 1-24 hours post-lysis the optical density (O.D.) of each well was checked using ELISA reader (at 570 nm, with 630 nm as reference). For assaying antigen- specific human CD8 T cell response, cells were washed and co-cultured in complete medium with the respective melanoma target cells at an effector-to-target ratio of 1:1 for 24 hours. IFN-g, TNF-a and GM-CSF secreted to the growth medium was monitored with commercial ELISA kits (R&D Systems Minneapolis, MN).
Luciferase reporter assay for NF-KB activity
NF-KB activity was measured by transient transfection of the NF-KB-Luciferase reporter plasmid to various adherent cell lines together with the particular gene under study. Twelve to forty-eight hours post-transfection luciferase activity in the cell lysate was monitored by the Luciferase Assay Systems reagent (Promega), using Infinite M200 Pro microplate reader (Tecan, Mannedorf, Switzerland).
Co-culture experiments
Seven hours post-electroporation T cells and melanoma target cells were co-cultured for 18 hours in triplicates at an effector-to-target ratio of 1:1 for B3Z and 3:1 for human CD8 T cells. For analysis of cell surface markers T cells were subjected to flow cytometry analysis using FACSCalibur (BD). For monitoring cytokine secretion growth medium was analyzed with commercial ELISA kits.
Cytotoxicity assay
CD8 T cells and melanoma target cells were co-cultured as described above for the cytokine ELISA. After 18 hours of co-culture cells with growth medium were transferred to a FACS tube, centrifuged for 7 min at 1,500 RPM and the supernatant was assayed for target cell killing using a commercial kit for the lactate dehydrogenase (LDH) cell cytotoxicity assay (BioVision, Milpitas, CA).
Statistical analysis
All results are presented as mean ± SEM. ELISA results are shown as the mean of triplicates with standard error (SEM). Statistical significance was determined using multiple comparisons with a-parametric test, one-way ANOVA-Kruskal Wallis, in SPSS software or GraphPad Prism software.
Example 1. CD40-CARs induce stronger NFKB activation than 4-lBB-CARs
To create the new series of CARs we have employed the pGEM4Z/EGFP/A64 vector to produce a template DNA cassette for mRNA synthesis encoding a scFv derived from the anti- HLA-A2 mAh BB7.2, a Myc tag and the CD 8 a hinge at the ectodomain and the FcRy intracellular T cell-activating domain (Fig. 1).
As the CD28 transmembrane domain was reported to support better surface expression than 4- IBB [44], we decided to similarly assess CD40, CD28 and 4- IBB. For this purpose we constructed four 2nd generation CARs: 40(+)-g and CD28(+)-y, harboring the intact human CD40 or CD28 transmembrane and intracellular portion, respectively, and 40-g and 4-1BB-g, containing the transmembrane domain of CD28 and the intracellular domain of either CD40 or 4- IBB (Fig. 1). The two 3rd generation CARs comprise the CD28 transmembrane and intracellular portion followed by either CD40 or 4- IBB intracellular domain.
Using the Myc tag it was confirmed by flow cytometry that all these CARs are properly expressed at the cell surface of K562 cells following electroporation of in-vitro transcribed mRNA
(Fig. 2).
Proper cell surface expression and antigen-mediated T cell activation was assessed by
employing the reporter mouse T cell hybridoma B3Z. We performed a co-culture experiment, assessing the ability of each of the six CARs to confer on B3Z transfectants the ability to respond to HLA-A2 on the 579-A2 melanoma cells in comparison with the parental 579 cells (Fig. 3A). While all CARs endowed B3Z cells with the anticipated antigenic specificity which, except for 40(+)-g, was comparable in magnitude to that induced by the 2C11 anti-CD3 mAh, considerable level of antigen non-specific-response to the parental 579 cells was also evident. Interestingly, whereas the incorporation of the CD28 transmembrane domain in the 40-g CAR did not translate into higher level of surface expression, it did result in a more robust response compared to 40(+)- Y·
We went on to evaluate the ability of the new CARs to activate the NF-KB signaling pathway, as judged by an NF-KB -Lucif erase reporter assay in the HLA-A2(+) HEK293T cells. As can be seen in Fig. 3B, the 3rd generation CAR 28-40-g induced considerably stronger signaling than its 28-41BB-g counterpart. Superiority of the 2nd generation CARs 40(+)-g and 40-g over 41BB-g was also observed, while 28(+)-g was utterly inactive in this assay. Interestingly, in contrast to its weaker activation of the NFAT pathway in B3Z cells, expression of the 40(+)-g construct resulted in stronger NF-KB activation than 40-g.
Example 2. Antigen-mediated activation of human CD8 T cells
The functional properties conferred on human T cells were compared by the two pairs of 2nd and 3rd generation CARs following antigenic stimulus. To this end we purified CD8 T cells from peripheral blood samples of two HLA-A2(-) healthy donors. We transfected these cells with mRNA encoding each of the four CARs and irrelevant mRNA and then co-cultured transfectants with the 579-A2 and 579 melanoma cells. Following confirmation of amount and integrity of new mRNAs synthesized for the next series of experiments (not shown), mild surface expression following electroporation of CD8 T cells of the two donors was demonstrated (Not shown). Of note, unlike K562 cells, in which expression of 28-4-1BB-g was comparable to the other CARs tested, 28-4-1BB-g yielded relatively lower signal in the two unrelated CD8 T cell samples. In subsequent co-culture experiments, 579-A2, but not 579 cells induced upregulation of the CD25 and 4- IBB activation markers (Not shown). Similarly, only the antigen-positive 579-A2 cells induced secretion of the pro-inflammatory cytokines IFN-g (Fig. 4A, D), TNF-a (Fig. 4B, E), and GM-CSF (Fig. 4C, F). Although differences emerged between the response patterns of CD8 T cells of the two donors, all CARs potentiated clear antigen-specific induction of the three cytokines with no or only minimal secretion in the absence of antigen. We now assessed antigen -mediated
target cell killing (Figs. 5A-B). Here, too, all four CARs in the two CD8 T cell samples could significantly mediate antigen-specific target cell killing, with no discernible differences between CD40 and 4- IBB in either CAR generation. Regarding the relatively low level of expression of 28-4-1BB-g, it mediated effective cytotoxicity, comparable to that of 28-40-g in CD8 T cells of the two donors, attesting to full competence of this mRNA.
REFERENCES
1. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86:10024-8.
2. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90:720-4.
3. Gross G, Eshhar Z. Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy. Annu Rev Pharmacol Toxicol [Internet]. 2016 [cited 2016 Jan 12];56:59-83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26738472
4. Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med [Internet]. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.; 2016 [cited 2016 Jan 6];22:26-36. Available from: http://dx.doi.org/10.1038/nm.4015
5. Holzinger A, Barden M, Abken H. The growing world of CAR T cell trials: a systematic review. Cancer Immunol Immunother [Internet]. 2016 [cited 2016 Sep 19];65:1433-50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27613725
6. Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol [Internet]. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.; 2013 [cited 2014 Jul 11];14:1014—22. Available from: http ://dx . doi.org/ 10.1038/ni .2703
7. Crompton JG, Sukumar M, Restifo NP. Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy. Immunol Rev [Internet]. 2014;257:264-76. Available from: http://dx.doi.org/10. Ill 1/imr.12135
8. Stoiber S, Cadilha BL, Benmebarek M-R, Lesch S, Endres S, Kobold S, et al. Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy. Cells [Internet]. Multidisciplinary Digital Publishing Institute; 2019 [cited 2019 Jul 10];8:472. Available from: https://www.mdpi.eom/2073-4409/8/5/472
9. Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4- IBB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med [Internet]. 2015 [cited 2019 Jul 13] ;21 :581—90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25939063
10. Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G, et al. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Cancer Cell [Internet]. Elsevier; 2015 [cited 2015 Oct 14];28:415- 28. Available from: http://www.cell.com/article/S1535610815003359/fulltext
11. van der Stegen SJC, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov [Internet]. 2015 [cited 2015 Oct 17];14:499- 509. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26129802
12. Acuto O, Michel F. CD28-mediated co- stimulation: a quantitative support for TCR signalling. Nat Rev Immunol [Internet]. 2003 [cited 2015 Sep 9] ;3 :939— 51. Available from: http ://dx . doi.org/ 10.1038/nri 1248
13. Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 Costimulation:
From Mechanism to Therapy. Immunity [Internet]. 2016 [cited 2019 Jul 11] ;44:973— 88. Available from: https://linkinghub.elsevier.eom/retrieve/pii/S 1074761316301492
14. Deluca LS, Gommerman JL. Fine-tuning of dendritic cell biology by the TNF superfamily. Nat Rev Immunol [Internet] Affiliation: University of Toronto, 1 King’s College Circle, Toronto, ON M5S 1A8, Canada; 2012;12:339-51. Available from: http://www.scopus.com/inward/record.url7ekU2-s2.0-
84860244317 &partnerID=40&md5=cab0ad 17e7 daf227008b8cfd96b01 a7b
15. Lynch DH. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev [Internet]. Bainbridge Biopharma Consulting, Bainbridge Island, WA, USA. dhlynch@Gmail.com; 2008;222:277-86. Available from: http://www. ncbi.nlm.nih.gov/entrez/query .fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list _uids=18364008
16. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains [Internet]. Proc. Natl. Acad. Sci. U. S. A. Affiliation: Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, United States; Affiliation: Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Phil; 2009. p. 3360-5. Available from: http://www.scopus.com/inward/record.url7ekU2-s2.0-
62549097817&partnerID=40&md5=80e3aa7f896aa764fe036f3ee7b05651
17. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo. Mol Ther [Internet]. 2009 [cited 2019 Jul
12] ; 17: 1453—64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19384291
18. Kawalekar OU, O’ Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, et al. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity [Internet]. 2016 [cited 2019 Jul 12];44:712. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28843072
19. Gomes-Silva D, Mukherjee M, Srinivasan M, Krenciute G, Dakhova O, Zheng Y, et al. Tonic 4- IBB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep [Internet]. 2017 [cited 2018 Jul 24];21:17-26. Available from: http://linkinghub.elsevier.com/retrieve/pii/S2211124717312767
20. Bourgeois C, Rocha B, Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science (80- ) [Internet]. INSERM U345, Institut Necker, 156 Rue de Vaugirard, F-75730 Paris Cedex 15, France.; 2002;297:2060-3. Available from: http://www. ncbi.nlm.nih.gov/entrez/query .fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list _uids= 12242444
21. Munroe ME. Functional roles for T cell CD40 in infection and autoimmune disease: the role of CD40 in lymphocyte homeostasis. Semin Immunol [Internet]. Department of Microbiology, The University of Iowa, Iowa City, IA 52242, USA. melissa-munroe@uiowa.edu; 2009;21:283-8. Available from: http://www. ncbi.nlm.nih.gov/entrez/query .fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list _uids=19539498
22. Soong RS, Song L, Trieu J, Lee SY, He L, Tsai YC, et al. Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors. PLoS One. Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, United States of America; Department of General Surgery, Chang Gung Memorial Hospital at Keelung, Keelung City, Taiwan; Chang Gung University, College of Medicine, Taoyuan, ; 2014;9:e93162.
23. Levin N, Pato A, Cafri G, Eisenberg G, Peretz T, Margalit A, et al. Spontaneous Activation of Antigen-presenting Cells by Genes Encoding Truncated Homo-Oligomerizing Derivatives of CD40. J Immunother [Internet]. 2016 [cited 2017 Feb 26];40:39-50. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00002371 - 900000000-99550
24. Levin N, Weinstein-Marom H, Pato A, Itzhaki O, Besser MJ, Eisenberg G, et al. Potent Activation of Human T Cells by mRNA Encoding Constitutively Active CD40. J Immunol [Internet]. 2018 [cited 2018 Nov 30];201:2959-68. Available from:
http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.1701725
25. Weinstein-Marom H, Levin N, Pato A, Shmuel N, Sharabi-Nov A, Peretz T, et al. Combined Expression of Genetic Adjuvants Via mRNA Electroporation Exerts Multiple Immunostimulatory Effects on Antitumor T Cells. J Immunother [Internet]. 2019 [cited 2019 Mar 23];42:43-50. Available from: http://insights.ovid.com/crossref?an=00002371-201902000- 00002
26. Foster AE, Mahendravada A, Shinners NP, Chang W-C, Crisostomo J, Lu A, et al. Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40. Mol Ther [Internet]. 2017 [cited 2018 Sep 22];25:2176-88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28697888
27. Mata M, Gerken C, Nguyen P, Krenciute G, Spencer DM, Gottschalk S. Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models. Cancer Discov [Internet]. 2017 [cited 2018 Aug 17] ;7: 1306—19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28801306
28. Collinson-Pautz MR, Chang W-C, Lu A, Khalil M, Crisostomo JW, Lin P-Y, et al. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies. Leukemia [Internet]. 2019 [cited 2019 Sep ll];33:2195-207. Available from: http://www.nature.com/articles/s41375-019-0417-9
29. Narayanan P, Lapteva N, Seethammagari M, Levitt JM, Slawin KM, Spencer DM. A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J Clin Invest [Internet]. Affiliation: Department of Pathology and Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, United States; Affiliation: Diana Helis Henry Medical Research Foundation, New Orleans, LA, United States; Affiliation: Scott Department ; 2011;121:1524-34. Available from: http://www.scopus.com/inward/record.url7ekU2-s2.0- 79953308076&partnerID=40&md5=a3a418a0e2b41987d76761a6a9f5de2a
30. Xie P. TRAF molecules in cell signaling and in human diseases. J Mol Signal [Internet]. 2013 [cited 2019 Aug 28];8:7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23758787
31. Wong JS, Wang X, Witte T, Nie L, Carvou N, Kem P, et al. Stalk region of beta-chain enhances the coreceptor function of CD8. J Immunol [Internet]. American Association of Immunologists; 2003 [cited 2019 Aug 28];171:867-74. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8283028
32. Chen X, Zaro JL, Shen W-C. Fusion protein linkers: property, design and functionality.
Adv Drug Deliv Rev [Internet]. 2013 [cited 2016 Aug 18];65: 1357—69. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3726540&tool=pmcentrez&renderty pe=abstract
33. Reddy Chichili VP, Kumar V, Sivaraman J. Linkers in the structural biology of protein-protein interactions. Protein Sci [Internet]. 2013 [cited 2016 Aug 18];22:153-67. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3588912&tool=pmcentrez&renderty pe=abstract
34. Whitlow M, Bell BA, Feng SL, Filpula D, Hardman KD, Hubert SL, et al. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng [Internet]. 1993 [cited 2018 Mar 16];6:989-95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8309948
35. Matuskova M, Durinikov E. Retroviral Vectors in Gene Therapy. Adv Mol Retrovirology [Internet]. InTech; 2016 [cited 2019 Mar 21]. Available from: http://www.intechopen.com/books/advances-in-molecular-retrovirology/retroviral-vectors-in- gene-therapy
36. Izsvak Z, Ivies Z. Sleeping Beauty Transposition: Biology and Applications for Molecular Therapy. Mol Ther [Internet]. 2004 [cited 2019 May 27];9:147-56. Available from: http ://www .ncbi.nlm.nih.gov/pubmed/ 14759798
37. Miller AD, Law MF, Verma IM. Generation of helper- free amphotropic retroviruses that transduce a dominant-acting, methotrexate-resistant dihydrofolate reductase gene. Mol Cell Biol [Internet]. American Society for Microbiology (ASM); 1985 [cited 2020 Mar 7];5:431-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2985952
38. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol [Internet]. American Society for Microbiology (ASM); 1986 [cited 2019 Aug 28];6:2895-902. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3785217
39. Danos O, Mulligan RC. Safe and Efficient Generation of Recombinant Retroviruses with Amphotropic and Ecotropic Host Ranges [Internet]. Proc. Natl. Acad. Sci. U. S. A. National Academy of Sciences; 1988 [cited 2019 Aug 28]. p. 6460-4. Available from: https://www.jstor.org/stable/32039
40. Bregni M, Magni M, Siena S, Di Nicola M, Bonadonna G, Gianni A. Human peripheral blood hematopoietic progenitors are optimal targets of retroviral-mediated gene transfer. Blood. 1992;80:1418-22.
41. Xu L, Stahl SK, Dave HP, Schiffmann R, Correll PH, Kessler S, et al. Correction of the enzyme deficiency in hematopoietic cells of Gaucher patients using a clinically acceptable retroviral supernatant transduction protocol. Exp Hematol [Internet]. 1994 [cited 2020 Mar 7];22:223-30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8299741
42. Hughes PF, Thacker JD, Hogge D, Sutherland HJ, Thomas TE, Lansdorp PM, et al. Retroviral gene transfer to primitive normal and leukemic hematopoietic cells using clinically applicable procedures. J Clin Invest [Internet]. American Society for Clinical Investigation; 1992 [cited 2019 Aug 28];89:1817-24. Available from: http ://www .ncbi.nlm.nih.gov/pubmed/ 1601991
43. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res [Internet]. Center for Genetic and Cellular Therapies, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.; 2000;60:1028-34. Available from: http://www. ncbi.nlm.nih.gov/entrez/query .fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list _uids= 10706120
44. Bishop DC, Xu N, Tse B, O’Brien TA, Gottlieb DJ, Dolnikov A, et al. PiggyBac- Engineered T Cells Expressing CD 19-Specific CARs that Lack IgGl Fc Spacers Have Potent Activity against B-ALL Xenografts. Mol Ther [Internet]. 2018 [cited 2020 Apr 24];26:1883-95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29861327
Claims
1. A nucleic acid molecule comprising a nucleotide sequence encoding an activating chimeric antigen receptor (aCAR) comprising:
(i) an extracellular binding domain;
(ii) a transmembrane domain;
(iii) an intracellular domain; and
(iv) a flexible hinge domain linking the extracellular binding domain and the transmembrane domain, said flexible hinge domain comprising a cysteine residue capable of forming a cysteine bridge, wherein said intracellular domain is selected from:
(a) an intracellular domain comprising a first amino acid sequence comprising at least one signal transduction element derived from CD40, and a second amino acid sequence comprising at least one signal transduction element derived from an FcR gamma (g) chain, CD3 zeta (z) chain, or CD3 eta (h) chain, and lacking a MyD88 polypeptide, 2A self-cleaving peptide or a dimerizing domain;
(b) an intracellular domain comprising a first amino acid sequence comprising at least one signal transduction element derived from CD40 and a third amino acid sequence comprising at least one signal transduction element derived from CD28 or 4- IBB; and
(c) an intracellular domain comprising a first amino acid sequence comprising at least one signal transduction element derived from CD40, a second amino acid sequence comprising at least one signal transduction element derived from an FcR gamma (g) chain, CD3 zeta (z) chain, or CD3 eta (h) chain and a third amino acid sequence comprising at least one signal transduction element derived from CD28; and
(d) an intracellular domain comprising a first amino acid sequence comprising at least one signal transduction element derived from CD40 and lacking a MyD88 polypeptide or a dimerizing domain.
2. The nucleic acid molecule of claim 1, wherein said extracellular binding domain comprises (i) an antibody, derivative or fragment thereof, such as a humanized antibody; a human antibody; a functional fragment of an antibody; a single-domain antibody, such as a Nanobody; a recombinant antibody; and a single chain variable fragment (ScFv); (ii) an antibody mimetic, such as an affibody molecule; an affilin; an affimer; an affitin; an alphabody; an anticalin; an avimer; a DARPin; a fynomer; a Kunitz domain peptide; and a monobody; or (iii) an aptamer.
3. The nucleic acid molecule of claim 2, wherein said extracellular binding domain comprises an ScFv.
4. The nucleic acid molecule of claim 1, wherein said transmembrane domain is selected from the transmembrane domain of CD28, CD40, CDS-z, TLR1, TLR2, TLR4, TLR5, TLR9, and Fc receptor.
5. The nucleic acid molecule of claim 4, wherein said transmembrane domain is the transmembrane domain of CD28.
6. The nucleic acid molecule of claim 1, wherein said first amino acid sequence is the complete intracellular domain of CD40.
7. The nucleic acid molecule of claim 1, wherein said at least one signal transduction element of said second amino acid sequence is derived from an FcRy chain.
8. The nucleic acid molecule of claim 7, wherein said second amino acid sequence is the complete intracellular domain of an FcRy chain.
9. The nucleic acid molecule of claim 1, wherein said third amino acid sequence is the complete intracellular domain of CD28.
10. The nucleic acid molecule of claim 1, wherein said flexible hinge comprises a polypeptide selected from a hinge region of CD8a, CD8p, a hinge region of a heavy chain of IgG, and a hinge region of a heavy chain of IgD.
11. The nucleic acid molecule of claim 10, wherein said flexible hinge domain is the hinge domain of CD8a.
12. The nucleic acid molecule of claim 1, wherein said extracellular binding domain comprises (i) an antibody, derivative or fragment thereof, such as a humanized antibody; a human antibody; a functional fragment of an antibody; a single-domain antibody, such as a Nanobody; a recombinant antibody; and a single chain variable fragment (ScFv); (ii) an antibody mimetic, such as an affibody molecule; an affilin; an affimer; an affitin; an alphabody; an anticalin; an avimer; a DARPin; a fynomer; a Kunitz domain peptide; and a monobody; or (iii) an aptamer; said transmembrane domain is selected from the transmembrane domain of CD28, CDS-z, TLR1, TLR2, TLR4, TLR5, TLR9, and Fc receptor; said first amino acid sequence is the complete intracellular domain of CD40; said at least one signal transduction element of said second amino
acid sequence is derived from an FcRy chain; said third amino acid sequence is the complete intracellular domain of CD28; and said flexible hinge comprises a polypeptide selected from a hinge region of CD8a, CD8P, a hinge region of a heavy chain of IgG, and a hinge region of a heavy chain of IgD.
13. The nucleic acid molecule of claim 12, wherein said extracellular binding domain comprises an ScFv; said transmembrane domain is the transmembrane domain of CD28; said second amino acid sequence is the complete intracellular domain of an FcRy chain; and said flexible hinge domain is the flexible hinge domain of CD8a.
14. The nucleic acid molecule of any one of claims 1 to 13, wherein said intracellular domain comprises a tandem arrangement of the complete intracellular domains of CD40-FcRy.
15. The nucleic acid molecule of claim 14, wherein said aCAR comprises a tandem arrangement of ScFv-hinge region of CD8a-CD28 transmembrane domain-intracellular domain essentially consisting of a tandem arrangement of the complete intracellular domains of CD40- FcRy.
16. The nucleic acid molecule of any one of claims 1 to 13, wherein said intracellular domain comprises a tandem arrangement of the complete intracellular domains of CD28-CD40-FcRy, wherein the intracellular domain of CD28 is optionally linked to the intracellular domain of CD40 via a linker.
17. The nucleic acid molecule of claim 16, wherein said intracellular domain comprises a tandem arrangement of the complete intracellular domains of CD28-linker-CD40-FcRy.
18. The nucleic acid molecule of claim 16 or 17, wherein said aCAR comprises a tandem arrangement of ScFv-hinge region of CD8a-CD28 transmembrane domain-intracellular domain essentially consisting of a tandem arrangement of the complete intracellular domains of CD28- CD40-FcRy, wherein the intracellular domain of CD28 is optionally linked to the intracellular domain of CD40 via a linker.
19. A composition comprising the nucleic acid molecule of any one of claims 1 to 18.
20. A vector comprising the nucleic acid molecule of any one of claims 1 to 18.
21. A mammalian T cell comprising the nucleic acid molecule of any one of claims 1 to 18, or the DNA vector of claim 20.
22. The mammalian T cell of claim 21, which is a CD4+ helper T cell or regulatory T cell (Treg).
23. The mammalian T cell of claim 21, which is a CD8+ effector T cell.
24. The mammalian T cell of any one of claims 21 to 23, expressing on its surface said aCAR.
25. The mammalian Treg of any one of claims 21 to 24, which is a human T cell.
26. A method of preparing allogeneic or autologous aCAR T cells, the method comprising contacting T cells with the nucleic acid molecule of any one of claims 1 to 18; or a vector of claim 20, thereby preparing allogeneic or autologous aCAR T cells.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20864247.0A EP4028526A4 (en) | 2019-09-11 | 2020-09-10 | Chimeric antigen receptor comprising cd40 cytoplasmic domain and uses thereof |
US17/641,949 US20220306723A1 (en) | 2019-09-11 | 2020-09-10 | Chimeric antigen receptor comprising cd40 cytoplasmic domain and uses thereof |
JP2022515811A JP2022547967A (en) | 2019-09-11 | 2020-09-10 | Chimeric antigen receptor containing CD40 cytoplasmic domain and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962898704P | 2019-09-11 | 2019-09-11 | |
US62/898,704 | 2019-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021048850A1 true WO2021048850A1 (en) | 2021-03-18 |
Family
ID=74866274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2020/050991 WO2021048850A1 (en) | 2019-09-11 | 2020-09-10 | Chimeric antigen receptor comprising cd40 cytoplasmic domain and uses thereof |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220306723A1 (en) |
EP (1) | EP4028526A4 (en) |
JP (1) | JP2022547967A (en) |
WO (1) | WO2021048850A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022203616A3 (en) * | 2021-03-24 | 2022-11-17 | Prince Of Songkla University | Cd28/cd40 co-stimulatory domain of the chimeric antigen receptor |
WO2022250431A1 (en) * | 2021-05-25 | 2022-12-01 | 주식회사 박셀바이오 | Monobody-based chimeric antigen receptor and immune cell including same |
US11697677B2 (en) | 2021-07-16 | 2023-07-11 | Instil Bio (Uk) Limited | Chimeric molecules providing targeted costimulation for adoptive cell therapy |
WO2023190550A1 (en) * | 2022-03-29 | 2023-10-05 | 学校法人自治医科大学 | Selective regulatory gene (srg) system for genetically modified immune cell therapy |
US11945876B2 (en) | 2021-06-16 | 2024-04-02 | Instil Bio (Uk) Limited | Receptors providing targeted costimulation for adoptive cell therapy |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016036746A1 (en) * | 2014-09-02 | 2016-03-10 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA44314A (en) * | 2015-11-05 | 2018-09-12 | Juno Therapeutics Inc | CHEMERICAL RECEPTORS CONTAINING TRAF-INDUCING DOMAINS, AND ASSOCIATED COMPOSITIONS AND METHODS |
CN107287163B (en) * | 2016-12-28 | 2019-03-15 | 时力生物科技(北京)有限公司 | Express the dendritic cells and application thereof of Chimeric antigen receptor |
US11976121B2 (en) * | 2017-07-20 | 2024-05-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CD123-binding chimeric antigen receptors |
-
2020
- 2020-09-10 US US17/641,949 patent/US20220306723A1/en active Pending
- 2020-09-10 JP JP2022515811A patent/JP2022547967A/en active Pending
- 2020-09-10 EP EP20864247.0A patent/EP4028526A4/en active Pending
- 2020-09-10 WO PCT/IL2020/050991 patent/WO2021048850A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016036746A1 (en) * | 2014-09-02 | 2016-03-10 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides |
Non-Patent Citations (5)
Title |
---|
KUHN NICHOLAS F; PURDON TERENCE J; VAN LEEUWEN DAYENNE G; LOPEZ ANDREA V; CURRAN KEVIN J; DANIYAN ANTHONY F; BRENTJENS RENIER: "CD 40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response", CANCER CELL, vol. 35, no. 3, 18 March 2019 (2019-03-18), pages 473 - 488, XP085638453, DOI: 10.1016/j.ccell.20 19.02.006 * |
MATA, MELINDA ET AL.: "Inducible activation of MyD88 and CD 40 in CAR T cells results in controllable and potent antitumor activity in preclinical solid tumor models", CANCER DISCOVERY, vol. 7, no. 11, 11 August 2017 (2017-08-11), pages 1306 - 1319, XP055497496, Retrieved from the Internet <URL:https://cancerdiscovery.aacrjournals.org/content/7/ll/1306.abstract> [retrieved on 20201012], DOI: 10.1158/2159-8290 * |
OFIR LEVIN-PIAEDA: "CD 40 costimulation enhances CAR-T cell activation", PRECISION MEDICINE IN THE PRISM OF IMMUNOLOGY AND CANCER, THE JOINT SCIENTIFIC MEETING OF IIS-ISCR CONFERENCE, 25 September 2019 (2019-09-25), pages 1 - 2, XP055802908, Retrieved from the Internet <URL:https://program.eventact.com/lecture?id=204321&code=4360912> * |
RAFIQ, SARWISH ET AL.: "Engineering strategies to overcome the current roadblocks in CAR T cell therapy", NATURE REVIEWS CLINICAL ONCOLOGY, vol. 17, no. 3, 17 December 2019 (2019-12-17), pages 147 - 167, XP037038725, Retrieved from the Internet <URL:https://www.nature.com/articles/s41571-019-0297-y> [retrieved on 20201012], DOI: 10.1038/ s 41571-019 -0297-y * |
See also references of EP4028526A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022203616A3 (en) * | 2021-03-24 | 2022-11-17 | Prince Of Songkla University | Cd28/cd40 co-stimulatory domain of the chimeric antigen receptor |
WO2022250431A1 (en) * | 2021-05-25 | 2022-12-01 | 주식회사 박셀바이오 | Monobody-based chimeric antigen receptor and immune cell including same |
US11945876B2 (en) | 2021-06-16 | 2024-04-02 | Instil Bio (Uk) Limited | Receptors providing targeted costimulation for adoptive cell therapy |
US11697677B2 (en) | 2021-07-16 | 2023-07-11 | Instil Bio (Uk) Limited | Chimeric molecules providing targeted costimulation for adoptive cell therapy |
WO2023190550A1 (en) * | 2022-03-29 | 2023-10-05 | 学校法人自治医科大学 | Selective regulatory gene (srg) system for genetically modified immune cell therapy |
Also Published As
Publication number | Publication date |
---|---|
JP2022547967A (en) | 2022-11-16 |
EP4028526A4 (en) | 2023-08-30 |
EP4028526A1 (en) | 2022-07-20 |
US20220306723A1 (en) | 2022-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11958892B2 (en) | Use of ICOS-based cars to enhance antitumor activity and car persistence | |
US11597754B2 (en) | Use of the CD2 signaling domain in second-generation chimeric antigen receptors | |
US20220306723A1 (en) | Chimeric antigen receptor comprising cd40 cytoplasmic domain and uses thereof | |
US20220056116A1 (en) | Compositions and Methods for Generating a Persisting Population of T Cells Useful for the Treatment of Cancer | |
US20220281944A1 (en) | Spycatcher and spytag: universal immune receptors for t cells | |
US20210177902A1 (en) | Ror-1 specific chimeric antigen receptors and uses thereof | |
KR20190102259A (en) | Regulation of Polypeptide Expression Through a Novel Gene Switch Expression System | |
US20230074800A1 (en) | Car-t cell therapies with enhanced efficacy | |
CN113423726A (en) | Receptor providing targeted co-stimulation for adoptive cell therapy | |
KR20210021493A (en) | MUC16 specific chimeric antigen receptor and uses thereof | |
KR20210057750A (en) | MR1 restricted T cell receptor for cancer immunotherapy | |
WO2023241522A1 (en) | T cell receptor targeting kras g12v mutant polypeptide, and use thereof | |
CN117024598A (en) | Long-acting Meso-B7H3 double-target chimeric antigen receptor and application thereof | |
CN115397439A (en) | Quantitative control of engineered cellular activity of expression universal immunoreceptors | |
RU2795198C2 (en) | Muc16-specific chimeric antigen receptors and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20864247 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022515811 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020864247 Country of ref document: EP Effective date: 20220411 |